Π ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ΅
ΠΠ°Π΅Π½Π½Π΅ΠΊ:
- ΠΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΡΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΠΏΠΎΠ½ΡΠΊΠΈΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ Π³Π΅ΠΏΠ°ΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ΄ΡΠ»ΡΡΠΎΡ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΡΠΊΡΠ΅ΠΏΠ»Π΅Π½ΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ°.
- ΠΡΠ» ΠΈΠ·ΠΎΠ±ΡΠ΅ΡΡΠ½ Π² Π―ΠΏΠΎΠ½ΠΈΠΈ Π² 1956 Π³ΠΎΠ΄Ρ ΠΈ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ Π² 30 ΡΡΡΠ°Π½Π°Ρ ΠΌΠΈΡΠ°
Π€Π°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π³ΡΡΠΏΠΏΠ°:
ΠΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅Π΅ ΠΈ Π³Π΅ΠΏΠ°ΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡΠ½ΠΎΠ΅ ΡΡΠ΅Π΄ΡΡΠ²ΠΎ.
ΠΡΠΏΡΡΠΊΠ°Π΅ΡΡΡ ΠΠ°Π΅Π½Π½Π΅ΠΊ Π² Π°ΠΌΠΏΡΠ»Π°Ρ
ΠΏΠΎ 2 ΠΌΠ».
Π Π΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ΅ ΡΠ΄ΠΎΡΡΠΎΠ²Π΅ΡΠ΅Π½ΠΈΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π΄ΡΡΠ²Π° β013851/01
ΠΡ ΠΎΠ΄ΠΈΡ Π² ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΠ΅Π΅ΡΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=132da942-bff2-4c40-9238-2c6807d0f52f&t=

- Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ Π² ΠΠ°Π΅Π½Π½Π΅ΠΊ ΡΡΡΡΠΊΡΡΡΠ½ΠΎ-ΠΏΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π΅ΡΠ΅ΡΡΠ², ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠΈΡ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ ΠΆΠΈΠ·Π½Π΅Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΡ, ΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΡ ΠΏΠ΅ΠΏΡΠΈΠ΄ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ Π°ΠΊΡΠΈΠ²ΠΈΠ·ΠΈΡΡΡΡ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ ΠΏΡΠΎΡΠ΅ΡΡΡ ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠΈ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, ΠΎΠ±ΡΡΠ»Π°Π²Π»ΠΈΠ²Π°ΡΡ Π²ΡΡΠΎΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ ΠΏΡΠΈ ΡΡΠΎΠΌ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.
- ΠΠ°Π΅Π½Π½Π΅ΠΊ β ΠΌΠ½ΠΎΠ³ΠΎΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ, ΡΠΎΡΡΠ°Π² ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Π½Π΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ ΠΏΠ΅ΠΏΡΠΈΠ΄Π°ΠΌΠΈ. ΠΠΎΠΌΠΈΠΌΠΎ ΠΏΠ΅ΠΏΡΠΈΠ΄ΠΎΠ², ΠΈΠ½Π³ΡΠ΅Π΄ΠΈΠ΅Π½ΡΡ ΠΠ°Π΅Π½Π½Π΅ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π²Π΅ΡΠ΅ΡΡΠ²: Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ°ΠΌΠΈ, Π²ΠΈΡΠ°ΠΌΠΈΠ½Π°ΠΌΠΈ ΠΈ ΠΌΠΈΠΊΡΠΎ- ΠΈ ΠΌΠ°ΠΊΡΠΎΡΠ»Π΅ΠΌΠ΅Π½ΡΠ°ΠΌΠΈ. ΠΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΎΠ±ΡΡΡΠ½ΡΡΡΡΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΡΠΈΠ½Π΅ΡΠ³ΠΈΡΠ½ΡΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΏΠ΅ΠΏΡΠΈΠ΄ΠΎΠ², ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΈ Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡ, Π½ΠΎ ΠΈ Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΌΠ°ΠΊΡΠΎ- ΠΈ ΠΌΠΈΠΊΡΠΎΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ², Π²ΠΈΡΠ°ΠΌΠΈΠ½ΠΎΠ².
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΡ ΠΠ°Π΅Π½Π½Π΅ΠΊ:
- ΠΠ΅ΠΏΠ°ΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡΠ½ΡΠΉ
- ΠΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠΈΠΉ
ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ
- ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΠ°Π΅Π½Π½Π΅ΠΊ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° Π±ΠΎΠ»Π΅Π΅ 60 Π»Π΅ΡΠ½ΠΈΠΌ ΠΎΠΏΡΡΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π―ΠΏΠΎΠ½ΠΈΠΈ.
- ΠΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΡΡΡ Π² Π―ΠΏΠΎΠ½ΠΈΠΈ ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠΎΠΉ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ·Π΄ΠΎΡΠΎΠ²Π»Π΅Π½ΠΈΡ.
- ΠΡΡΠΈΡΡΠ΅ΡΡΡ ΠΈ Π΄ΠΎΡΠΈΡΡΠ΅ΡΡΡ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΌ Π΄Π΅ΠΏΠ°ΡΡΠ°ΠΌΠ΅Π½ΡΠΎΠΌ ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΡΠ°Ρ ΠΎΠ²ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΠΎΠΉ Π―ΠΏΠΎΠ½ΠΈΠΈ.
ΠΠ½ΡΡΡΡΠΊΡΠΈΡ Π‘ΠΎΡΡΠ°Π²
Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ Π΄ΡΠ΅Π²Π½Π΅ΠΉ Π»Π΅Π³Π΅Π½Π΄Π΅, ΡΠΈΠ»ΠΎΡΠΎΡΡΠΊΠΈΠΉ ΠΊΠ°ΠΌΠ΅Π½Ρ Π»ΡΠ±ΠΎΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²ΠΎ ΠΏΡΠ΅Π²ΡΠ°ΡΠ°Π΅Ρ Π² Π·ΠΎΠ»ΠΎΡΠΎ. ΠΠ½ΠΎΠ³ΠΈΠ΅ ΡΡΠ΅Π½ΡΠ΅ ΡΡΠ΅Π΄Π½ΠΈΡ Π²Π΅ΠΊΠΎΠ² ΠΏΠΎΡΠ²ΡΡΠΈΠ»ΠΈ ΡΠ²ΠΎΠΈ ΠΆΠΈΠ·Π½ΠΈ Π΅Π³ΠΎ Π±Π΅Π·ΡΡΠΏΠ΅ΡΠ½ΠΎΠΌΡ ΠΏΠΎΠΈΡΠΊΡ.
Π―ΠΏΠΎΠ½ΡΡ ΠΏΠΎΠ΄Ρ Π²Π°ΡΠΈΠ»ΠΈ ΡΡΡΠ°ΡΠ΅ΡΡ Π°Π»Ρ ΠΈΠΌΠΈΠΊΠΎΠ². Π ΡΡΠ΄Ρ ΠΏΠΎ Π²ΡΠ΄Π°ΡΡΠΈΠΌΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ, ΠΈΠΌ Π²ΡΠ΅-ΡΠ°ΠΊΠΈ ΡΠ΄Π°Π»ΠΎΡΡ ΠΎΡΠΊΡΡΡΡ ΡΠΈΠ»ΠΎΡΠΎΡΡΠΊΠΈΠΉ ΠΊΠ°ΠΌΠ΅Π½Ρ. ΠΡΠΎ Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°Ρ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ «ΠΠ°Π΅Π½Π½Π΅ΠΊ» (Laennec Placenta Extract) β ΠΊΡΠ°ΠΉΠ½Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΡΡΠΈΠΌΡΠ»ΡΡΠΎΡ ΠΆΠΈΠ·Π½Π΅Π½Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ, ΡΠΎΠ·Π΄Π°Π½Π½ΡΠΉ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ.Β
ΠΠ½ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎ ΠΎΠΌΠΎΠ»Π°ΠΆΠΈΠ²Π°Π΅Ρ, ΠΎΠ±Π½ΠΎΠ²Π»ΡΠ΅Ρ ΠΈ ΠΎΠ·Π΄ΠΎΡΠ°Π²Π»ΠΈΠ²Π°Π΅Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌ ΠΈΠ·Π½ΡΡΡΠΈ:
- ΡΡΠΈΠ»ΠΈΠ²Π°Π΅Ρ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅Ρ,
- Π²ΠΎΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°Π΅Ρ ΠΏΠ΅ΡΠ΅Π½Ρ ΠΈ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΠΎΠ±ΡΠ΅ΠΉ Π΄Π΅ΡΠΎΠΊΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ°,
- ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ ΠΌΠΎΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ Π»ΠΈΡΡΠΈΠ½Π³Π°,
- Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΠ²Π΅ΠΆΠ°Π΅Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΊΠΎΠΆΠΈ,
- ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ ΡΠ»ΡΡΡΠ°Π΅Ρ ΡΠ°Π±ΠΎΡΡ Π²ΡΠ΅Ρ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ ΠΎΡΠ³Π°Π½ΠΎΠ²,
- Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΡΠ΅Ρ Π²ΡΠ·ΠΊΠΎΡΡΡ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΡΠ»ΡΠΆΠΈΡ ΡΠ΅ΠΌ ΡΠ°ΠΌΡΠΌ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΎΠΉ ΠΈΠ½ΡΠ°ΡΠΊΡΠΎΠ² ΠΈ ΠΈΠ½ΡΡΠ»ΡΡΠΎΠ²,
- ΡΠ»ΡΡΡΠ°Π΅Ρ ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠ΅ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅, Π·ΡΠ΅Π½ΠΈΠ΅, ΠΏΠ°ΠΌΡΡΡ, ΡΠ»ΡΡ ,
- ΡΠ½ΠΈΠΌΠ΅Ρ ΡΡΡΠ΅ΡΡ ΠΈ Π±Π΅ΡΡΠΎΠ½Π½ΠΈΡΡ, ΠΎΠ±ΡΠ΅Π΅ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠ΅;
- ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΡΠ΅Ρ Π½Π° ΠΎΡΠ³Π°Π½Ρ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΡΠ°Π·Π° ΠΈ ΡΠΈΠ½ΡΠ΅Π· ΠΏΠΎΠ»ΠΎΠ²ΡΡ Π³ΠΎΡΠΌΠΎΠ½ΠΎΠ², ΡΡΡΡΠ°Π½ΡΠ΅Ρ ΡΡΠΈΠ³ΠΈΠ΄Π½ΠΎΡΡΡ ΠΈ ΠΏΠΎΠ»ΠΎΠ²ΡΡ ΡΠ»Π°Π±ΠΎΡΡΡ.
ΠΡ ΡΠΆΠ΅ Π·Π½Π°Π΅ΡΠ΅, ΡΡΠΎ ΡΡΠ°ΡΡΡΠ΅ Π½Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π΄Π΅Π½ΡΠ³Π°ΠΌΠΈ. ΠΡ ΡΠΆΠ΅ ΠΏΠΎΠ½ΡΠ»ΠΈ, ΡΡΠΎ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΠΏΠΎΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ°ΡΡΠ½ΠΎΠ΅ ΠΆΠ΅Π»Π°Π½ΠΈΠ΅ Π±ΡΡΡ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌ ΠΈ ΠΆΠΈΡΡ Π΄ΠΎΠ»Π³ΠΎ, ΡΡΠΎΠ±Ρ Π½Π°ΡΠ»Π°ΠΆΠ΄Π°ΡΡΡΡ Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΡΠΌ. ΠΠΌΠ΅Π½Π½ΠΎ ΡΡΡ Π·Π°Π΄Π°ΡΡ ΠΈ ΡΠ΅ΡΠ°Π΅Ρ «ΠΠ°Π΅Π½Π½Π΅ΠΊ».
Π ΠΊΠ°ΠΊΠΎΠΌ-ΡΠΎ ΡΠΌΡΡΠ»Π΅, «ΠΠ°Π΅Π½Π½Π΅ΠΊ» ΠΌΠΎΠΆΠ½ΠΎ ΡΡΠ°Π²Π½ΠΈΡΡ Ρ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π°ΠΌΠΈ. ΠΠΏΡΠΎΡΠ΅ΠΌ, Π΄Π°ΠΆΠ΅ Π² ΡΠ°ΠΌΡΠ΅ «ΠΏΡΠΎΠ΄Π²ΠΈΠ½ΡΡΡΠ΅» Π²ΠΈΡΠ°ΠΌΠΈΠ½Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ Π½Π΅ Π±ΠΎΠ»Π΅Π΅ 30 ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎ ΡΠΈΠ½ΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΠ²Π°ΠΈΠ²Π°ΡΡΡΡ ΠΌΠ°ΠΊΡΠΈΠΌΡΠΌ Π½Π° 80%.
Π’Π°ΠΊΠΎΠΉ ΡΠ½ΠΈΠΊΠ°Π»ΡΠ½ΡΠΉ ΡΠΎΡΡΠ°Π² ΡΠ°Π·Π½ΠΎΡΡΠΎΡΠΎΠ½Π½Π΅ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΡΠ΅Ρ Π½Π° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°.
ΠΠ»Π°ΡΠ΅Π½ΡΠ° ΠΠ°Π΅Π½Π½Π΅ΠΊ Π²ΠΎ Π²ΡΠ΅ΠΌ ΠΌΠΈΡΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»Π΅Π΅ 80 ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
- Π°Π»Π»Π΅ΡΠ³ΠΈΡ ΠΈ Π°ΡΡΠΌΠ°,
- Π°Π΄Π΅Π½ΠΎΠΌΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ,
- Π²ΡΠΏΠ°Π΄Π΅Π½ΠΈΠ΅ Π²ΠΎΠ»ΠΎΡ,
- ΡΠΈΠΌΠΏΡΠΎΠΌΡ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡΠ°, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ Ρ ΠΆΠ΅Π½ΡΠΈΠ½, ΠΎΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠΈΡ ΡΡ ΠΎΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΠΠ’,
- ΠΌΡΠΆΡΠΊΠΎΠΉ ΠΊΠ»ΠΈΠΌΠ°ΠΊΡ,
- Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΎΠ±ΠΌΠ΅Π½Π° Π²Π΅ΡΠ΅ΡΡΠ², ΡΠ½ΡΡΠ΅Π·,
- ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ΅ ΠΈ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠ΅ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅,
- ΡΠ·Π²Π° ΠΈ ΡΠ°ΠΊ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°,
- ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ Π·Π°ΠΆΠΈΠ²Π»ΡΠ΅Ρ ΡΠ°Π½Ρ, Π±ΠΎΡΠ΅ΡΡΡ Ρ ΠΊΠ΅Π»ΠΎΠΈΠ΄Π½ΡΠΌΠΈ ΡΡΠ±ΡΠ°ΠΌΠΈ,
- Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ°Π»ΠΎΡΡΡ,
- Π±ΠΎΠ»Π΅Π·Π½Π΅Π½Π½ΡΠ΅ ΠΌΠ΅Π½ΡΡΡΡΠ°ΡΠΈΠΈ,
- Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²,
- Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΊΠΎΠΆΠΈ,
- Π½Π΅Π²ΡΠ°Π»Π³ΠΈΠΈ, ΠΌΠΈΠ³ΡΠ΅Π½ΠΈ ΠΈ Π½Π΅Π²ΡΠΎΠ·Ρ,
- ΠΎΡΡΠ΅ΠΎΡ ΠΎΠ½Π΄ΠΎΡΠΎΠ· ΠΈ Ρ.Π΄.
Π «ΠΠ»Π°ΡΠΈΠ½Π΅Π½ΡΠ°Π»» ΠΌΡ Π΄ΠΎΠ±ΠΈΠ²Π°Π΅ΠΌΡΡ ΠΏΠΎΡΡΡΡΠ°ΡΡΠΈΡ ΡΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ², ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΈΡΡ Ρ «ΠΠ°Π΅Π½Π½Π΅ΠΊ» Π΄Π»Ρ ΠΏΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈ Π±ΡΡΡΡΠΎΠΉ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ.
ΠΠΎΡΠ΅ΠΌΡ Π² ΠΌΠΈΡΠΎΠ²ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅ «ΠΠ°Π΅Π½Π½Π΅ΠΊ» Π·Π°Π²ΠΎΠ΅Π²Π°Π» ΡΠ°ΠΊΠΎΠ΅ ΠΏΡΠΈΠ·Π½Π°Π½ΠΈΠ΅? ΠΠ΅ ΡΠΎΠ»ΡΠΊΠΎ Π·Π° ΡΠ²ΠΎΠΉ Π±ΠΎΠ³Π°ΡΡΠΉ ΡΠΎΡΡΠ°Π².
ΠΡΠ΅ ΠΌΡ Π·Π½Π°Π΅ΠΌ, ΡΡΠΎ ΠΏΡΠΈ ΠΏΡΠΈΠ΅ΠΌΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΠ°ΠΊ ΠΈΠ»ΠΈ ΠΈΠ½Π°ΡΠ΅ ΡΡΡΠ°Π΄Π°ΡΡ Π΄ΡΡΠ³ΠΈΠ΅ ΠΎΡΠ³Π°Π½Ρ. Π ΠΌΡ «ΠΏΠΎ ΡΠΌΠΎΠ»ΡΠ°Π½ΠΈΡ» ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π΅ΠΌ ΡΡΠΈ ΠΏΡΠ°Π²ΠΈΠ»Π° ΠΈΠ³ΡΡ.
ΠΡΠ΄ΡΡΠΈ ΡΡΠ΅
Π² ΡΠ΅ΠΌ ΠΏΠΎΠΌΠΎΠ³Π°Π΅Ρ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ?
ΠΠΎΠ³Π΄Π° ΠΌΠ½Π΅, ΠΊΠ°ΠΊ Π±ΡΡΡΠΈ-ΡΠ΅Π΄Π°ΠΊΡΠΎΡΡ, ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠΈΠ»ΠΈ ΠΈΡΠΏΡΡΠ°ΡΡ Π½Π° ΡΠ΅Π±Π΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ» (Laennec), ΡΠ°Π·Π΄ΡΠΌΡΠ²Π°Π»Π° Ρ Π΄ΠΎΠ»Π³ΠΎ. Π’ΠΎΡ ΡΠ°ΠΌΡΠΉ ΡΠ»ΡΡΠ°ΠΉ, ΠΊΠΎΠ³Π΄Π° Β«ΠΈ Ρ ΠΎΡΠ΅ΡΡΡ ΠΈ ΠΊΠΎΠ»Π΅ΡΡΡΒ».
Π‘ ΠΎΠ΄Π½ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ, ΡΠΌΡΡΠ°Π»ΠΎ ΡΡΡΡΠ΅, ΠΈΠ· ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΡΠΏΠΎΠ½ΡΡ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ, β ΡΡΠΎ ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠ°Ρ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°. Π‘ Π΄ΡΡΠ³ΠΎΠΉ β ΠΊΠ°ΠΊ ΡΠ°Π· ΡΠΏΠΎΠ½ΡΡ, ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠ΅ ΡΠ²ΠΎΠΈΠΌΠΈ Π½Π°ΡΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΡΠ²Π°ΠΌΠΈ ΠΈ ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΡΠΌΠΈ, ΡΠΆΠ΅ Π½Π΅ ΠΏΠ΅ΡΠ²ΡΠΉ Π΄Π΅ΡΡΡΠΎΠΊ Π»Π΅Ρ ΠΈΡΡΠ»Π΅Π΄ΡΡΡ ΠΈ Π²Π½Π΅Π΄ΡΡΡΡ Π² ΠΌΠ°ΡΡΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΡ ΡΠΎΠ³ΠΎ ΠΆΠ΅ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ» Π½Π°ΡΠ°Π» Π΄ΠΎΠΊΡΠΎΡ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ Π½Π°ΡΠΊ Π₯ΠΈΡΠ΄Π° ΠΡΠ½ΡΠ°ΡΠΎ Π² Π΄Π°Π»Π΅ΠΊΠΎΠΌ 1953 Π³ΠΎΠ΄Ρ, ΠΊΠΎΠ³Π΄Π° ΠΏΠ΅ΡΠ΅Π΄ ΡΡΠ΅Π½ΡΠΌΠΈ ΡΡΠΎΡΠ»Π° Π·Π°Π΄Π°ΡΠ° ΠΈΠ·ΠΎΠ±ΡΠ΅ΡΡΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²ΠΎ Π΄Π»Ρ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° Π² ΠΏΠΎΠΌΠΎΡΡ ΠΏΠΎΡΡΡΠ°Π΄Π°Π²ΡΠΈΠΌ ΠΆΠΈΡΠ΅Π»ΡΠΌ Π₯ΠΈΡΠΎΡΠΈΠΌΡ ΠΈ ΠΠ°Π³Π°ΡΠ°ΠΊΠΈ.
ΠΠΎΠΊΡΠΎΡ ΠΡΠ½ΡΠ°ΡΠΎ, Π²Π΄ΠΎΡ Π½ΠΎΠ²Π»Π΅Π½Π½ΡΠΉ Π½Π°ΡΡΠ½ΡΠΌΠΈ ΡΡΡΠ΄Π°ΠΌΠΈ ΡΠΎΠ²Π΅ΡΡΠΊΠΎΠ³ΠΎ Π°ΠΊΠ°Π΄Π΅ΠΌΠΈΠΊΠ° Π.Π. Π€ΠΈΠ»Π°ΡΠΎΠ²Π° ΠΏΠΎ ΡΠΊΠ°Π½Π΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΠ΄Π΅Π»Π°Π» ΡΡΠ°Π²ΠΊΡ Π½Π° ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π» Π½Π° Π΅Π΅ ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ. ΠΠΎ Π²ΡΡΡΠ½ΠΈΠ»ΠΎΡΡ, ΡΡΠΎ Π½ΠΎΠ²ΠΈΠ½ΠΊΠ° ΠΈΠΌΠ΅Π΅Ρ ΠΊΡΠ΄Π° Π±ΠΎΠ»Π΅Π΅ ΡΠΈΡΠΎΠΊΠΈΠΉ ΡΠΏΠ΅ΠΊΡΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΡΠ΅ΠΌ ΠΏΡΠΎΡΡΠΎ Π³Π΅ΠΏΠ°ΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΈΡ. Π ΠΈΠΌΠ΅Π½Π½ΠΎ β ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΠΈΡ ΠΈ ΠΎΠΌΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅.
ΠΠΊΡΠΏΠ΅ΡΡΡ Π¦Π΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΡΠΈΡΡΡΠ° Π΄Π΅ΡΠΌΠ°ΡΠΎΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ www.cidk.ru:

ΠΠΎΠΆΠ΅Π²Π½ΠΈΠΊΠΎΠ²Π° ΠΠ°ΡΠ°Π»ΡΡ ΠΠ»Π°Π΄ΠΈΠΌΠΈΡΠΎΠ²Π½Π°,
Π²ΡΠ°Ρ-Π΄Π΅ΡΠΌΠ°ΡΠΎΠ²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³, ΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³, ΡΡΠΈΡ ΠΎΠ»ΠΎΠ³

Π―ΠΊΡΠ½ΠΈΠ½Π° ΠΠΊΠ°ΡΠ΅ΡΠΈΠ½Π° ΠΠ»Π°Π΄ΠΈΠΌΠΈΡΠΎΠ²Π½Π°,
ΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³-ΡΡΡΠ΅ΡΠΈΡΡ

Π‘ΠΎΠ±ΠΎΠ»Π΅Π²Π° ΠΠ²Π³Π΅Π½ΠΈΡ ΠΠ½Π΄ΡΠ΅Π΅Π²Π½Π°,
Π²ΡΠ°Ρ-ΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³
Β«βΠΠ°Π΅Π½Π½Π΅ΠΊβ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΊ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ βΡΠΌΠ½ΡΡ β ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², β Π³ΠΎΠ²ΠΎΡΠΈΡ Π²ΡΠ°Ρ-Π΄Π΅ΡΠΌΠ°ΡΠΎΠ²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³ ΠΠ°ΡΠ°Π»ΡΡ ΠΠΎΠΆΠ΅Π²Π½ΠΈΠΊΠΎΠ²Π°. β ΠΠ³ΠΎ Π°ΠΊΡΠΈΠ²Π½ΡΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡ ΡΠ°Π±ΠΎΡΠ°ΡΡ ΠΈΠΌΠ΅Π½Π½ΠΎ Π½Π° ΡΡ ΡΠΈΡΡΠ΅ΠΌΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ°, ΠΊΠΎΡΠΎΡΠ°Ρ Π½ΡΠΆΠ΄Π°Π΅ΡΡΡ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ. ΠΠ½ ΡΠ°ΠΌ Π²ΡΡΠ²Π»ΡΠ΅Ρ ΡΠ»Π°Π±ΡΠ΅ Π·Π²Π΅Π½ΡΡ ΠΈ ΠΏΡΠΈΡΡΡΠΏΠ°Π΅Ρ ΠΊ ΠΈΡ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π½Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΡΠΎΠ²Π½Π΅Β».
Π§ΡΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ Π² ΡΠ΅Π±Π΅ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ»?
ΠΡΠΊΠ»Π΅ΠΎΠ·ΠΈΠ΄Ρ, Π½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Ρ, ΠΏΠ΅ΠΏΡΠΈΠ΄Ρ, Π³Π»ΠΈΠΊΠΎΠ·Π°ΠΌΠΈΠ½ΠΎΠ³Π»ΠΈΠΊΠ°Π½Ρ, ΡΠ½Π·ΠΈΠΌΡ, 18 Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡ, ΡΡΠΈΡΡΠΎΠΏΠΎΡΡΠΈΠ½, ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½ Π³Π°ΠΌΠΌΠ°, ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Ρ 1-6, 8, 10, 12, ΠΌΠ°ΠΊΡΠΎΡΠ»Π΅ΠΌΠ΅Π½ΡΡ (N, P, C, S, Na, Mg, Ca, K), ΠΌΠΈΠΊΡΠΎΡΠ»Π΅ΠΌΠ΅Π½ΡΡ (Zn, Br, Si, Fe, Mn, Sc, Se, Cr, V, Cu, Li, B, Co), Π²ΠΈΡΠ°ΠΌΠΈΠ½Ρ (Π1, Π2, Π3, Π‘, D, Π Π ) ΠΈ 36 ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΎΡΡΠ°, ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΡ ΠΎΠ±Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠΈΠ½ΡΠ΅Π· ΠΊΠΎΠ»Π»Π°Π³Π΅Π½Π° ΠΈ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ Π½Π΅ΡΠ²Π½ΡΡ Π²ΠΎΠ»ΠΎΠΊΠΎΠ½.
Β«Π£ΠΌΠ½ΠΎΠ΅Β» Π»Π΅ΠΊΠ°ΡΡΡΠ²ΠΎ ΠΈΠ· Π―ΠΏΠΎΠ½ΠΈΠΈ Ρ Π²Π½ΡΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠΏΠΈΡΠΊΠΎΠΌ ΠΏΠΎΠ»Π΅Π·Π½ΡΡ Π²Π΅ΡΠ΅ΡΡΠ² β Π·Π²ΡΡΠΈΡ ΠΌΠ½ΠΎΠ³ΠΎΠΎΠ±Π΅ΡΠ°ΡΡΠ΅, ΠΎΠ΄Π½Π°ΠΊΠΎ Ρ ΠΎΡΠ΅ΡΡΡ ΡΠ·Π½Π°ΡΡ ΠΏΠΎΠ΄ΡΠΎΠ±Π½Π΅Π΅, ΡΡΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ° ΡΠ»ΡΠΆΠΈΡ ΡΡΡΡΠ΅ΠΌ Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ?
ΠΠ΅Π½Ρ ΡΡΠΏΠΎΠΊΠ°ΠΈΠ²Π°ΡΡ ΡΠ΅ΠΌ, ΡΡΠΎ ΠΎΡΠ±ΠΎΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎ Π»Π΅Π³Π°Π»Π΅Π½ ΠΈ ΡΡΠΈΡΠ΅Π½ β Π½ΠΈ ΠΎΠ΄ΠΈΠ½ ΠΌΠ»Π°Π΄Π΅Π½Π΅Ρ Π½Π΅ ΠΏΠΎΡΡΡΠ°Π΄Π°Π». Β«ΠΠΈΠΎΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΠ΅ Π΄Π»Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° βΠΠ°Π΅Π½Π½Π΅ΠΊβ, ΠΏΡΠΎΡ ΠΎΠ΄ΡΡ ΡΡΡΠΎΠΆΠ°ΠΉΡΠΈΠΉ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ·Π΄ΠΎΡΠΎΠ²Π»Π΅Π½ΠΈΡ Π―ΠΏΠΎΠ½ΠΈΠΈ, β Π·Π°ΡΠ²Π»ΡΠ΅Ρ Π½Π° ΡΠ²ΠΎΠ΅ΠΌ ΡΠ°ΠΉΡΠ΅ ΠΎΡΠΈΡΠΈΠ°Π»ΡΠ½ΡΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Ρ Π±ΡΠ΅Π½Π΄Π° Π² Π ΠΎΡΡΠΈΠΈ β ΠΊΠΎΡΠΏΠΎΡΠ°ΡΠΈΡ Rhana. ΠΠ»Π°ΡΠ΅Π½ΡΠ° ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ ΡΠΎΠ»ΡΠΊΠΎ Π² ΡΠΎΠΌ ΡΠ»ΡΡΠ°Π΅, Π΅ΡΠ»ΠΈ ΡΠΎΠ΄Ρ Π±ΡΠ»ΠΈ Π±Π»Π°Π³ΠΎΠΏΠΎΠ»ΡΡΠ½ΡΠΌΠΈ, ΡΡΠΎΠΊ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ β ΠΏΠΎΠ»Π½ΡΠΌ, Π° ΡΠΎΠΆΠ΅Π½ΠΈΡΠ° Π½ΠΈΠΊΠΎΠ³Π΄Π° Π½Π΅ Π²ΡΠ΅Π·ΠΆΠ°Π»Π° ΠΈΠ· Π―ΠΏΠΎΠ½ΠΈΠΈ. ΠΡΠ΄ΡΡΠΈΠ΅ Π΄ΠΎΠ½ΠΎΡΡ Π·Π°ΡΠ°Π½Π΅Π΅ Π΄Π°ΡΡ ΠΏΠΈΡΡΠΌΠ΅Π½Π½ΠΎΠ΅ ΡΠΎΠ³Π»Π°ΡΠΈΠ΅ Π½Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΠΈ ΠΏΡΠΎΠ²Π΅ΡΡΡΡΡΡ Π½Π° ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Π»ΡΠ±ΡΡ Π²Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ , ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΡ ΠΈ Π΄ΡΡΠ³ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉΒ».
ΠΠΎΠΌΠΈΠΌΠΎ ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ Π²ΠΎΠΏΡΠΎΡΠ° Π²ΠΎΠ»Π½ΡΠ΅Ρ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΠΈ Π² ΠΊΡΠΎΠ²Ρ ΡΡΠΆΠ΅ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ Π±ΠΈΠΎΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°.
Β«ΠΠ»Π°ΡΠ΅Π½ΡΠ° ΡΠ΅ΡΡΠΈΡΡΠ΅ΡΡΡ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΡΠ°Π·, Π½Π° Π²ΡΠ΅Ρ ΡΡΠ°ΠΏΠ°Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π°. ΠΠΎΠ»Π΅Π΅ ΡΠΎΠ³ΠΎ, ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΡΠΉ ΡΠΊΡΡΡΠ°ΠΊΡ ΠΎΠ±Π΅Π·Π·Π°ΡΠ°ΠΆΠΈΠ²Π°Π΅ΡΡΡ Π² ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΡΠ»ΠΎΠ²ΠΈΡΡ , ΡΡΠΎΠ±Ρ ΡΠ½ΠΈΡΡΠΎΠΆΠΈΡΡ ΠΌΠΈΠΊΡΠΎΠ±Ρ ΠΈ Π±Π°ΠΊΡΠ΅ΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΌΠΎΠ³ΡΡ Π² Π½Π΅ΠΌ ΠΏΡΠΈΡΡΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΈ Π½Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΡΡ ΡΠ΅ΡΡΠ°ΠΌΠΈ, β ΡΠ²Π΅ΡΡΠ΅Ρ ΡΠ°ΠΉΡ www.laennec.ru. β Π‘ΡΡΡΠ΅ ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΡ ΠΎΠ΄ΠΈΡ ΠΎΡΠΈΡΡΠΊΡ Π½Π° ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΌ ΡΡΠΎΠ²Π½Π΅, Π΄Π»Ρ ΡΡΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΌΠ½ΠΎΠ³ΠΎΡΡΡΠΏΠ΅Π½ΡΠ°ΡΠΎΠ³ΠΎ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ. Π’Π°ΠΊ ΡΡΠΎ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²ΡΡΠΎΠΊΠΎΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° ΡΠΊΡΡΡΠ°ΠΊΡΠΈΠΈ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ Π² ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ΅ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ ΠΎΡΡΡΡΡΡΠ²ΡΡΡ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΠΎΠΏΠ°ΡΠ½ΡΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°Β».
ΠΠ°ΠΊΠΎΠ½Π΅Ρ, ΠΌΠ½Π΅ Ρ ΠΎΡΠ΅ΡΡΡ Π·Π½Π°ΡΡ, ΡΠ΅Π³ΠΎ ΡΡΠΎΠΈΡ ΠΎΠΆΠΈΠ΄Π°ΡΡ ΠΎΡ ΠΊΡΡΡΠ° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ» Π»ΡΠ΄ΡΠΌ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΠΎΠΉ ΠΏΠ΅ΡΠ΅Π½ΡΡ?
Β«ΠΡΡΡ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΈΡ Π΄Π°Π΅Ρ ΡΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ: ΡΠ»ΡΡΡΠ°Π΅ΡΡΡ ΡΠ²Π΅Ρ ΠΈ ΡΡΡΡΠΊΡΡΡΠ° ΠΊΠΎΠΆΠΈ, ΡΡΡΡΠ°Π½ΡΠ΅ΡΡΡ ΠΎΡΠ΅ΡΠ½ΠΎΡΡΡ ΠΈ ΠΏΠ°ΡΡΠΎΠ·Π½ΠΎΡΡΡ, ΡΡΠΈΠ»ΠΈΠ²Π°Π΅ΡΡΡ ΡΠΎΠΊ Π»ΠΈΠΌΡΡ ΠΈ ΠΊΡΠΎΠ²ΠΈ, Π°ΠΊΡΠΈΠ²ΠΈΠ·ΠΈΡΡΡΡΡΡ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ, β ΠΎΠ±ΡΡΡΠ½ΡΠ΅Ρ ΠΌΠ½Π΅ Π²ΡΠ°Ρ-ΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³ ΠΠ²Π³Π΅Π½ΠΈΡ Π‘ΠΎΠ±ΠΎΠ»Π΅Π²Π°. β ΠΡ Π°ΠΊΠ½Π΅ βΠΠ°Π΅Π½Π½Π΅ΠΊβ Π½Π΅ Π²ΡΠ»Π΅ΡΠΈΡ, Π½ΠΎ ΠΎΠ±ΡΠ΅Π΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΊΠΎΠΆΠΈ ΡΠ»ΡΡΡΠΈΡΒ».
Π’Π°ΠΊΠΆΠ΅ Π½Π΅ Π»ΠΈΡΠ½ΠΈΠΌ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠΌ ΠΎΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π±ΡΠ΄Π΅Ρ:
β ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΠ½Π°;
β ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π±ΠΎΡΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ;
β ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ;
β ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΠΈ ΠΊ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌ ΠΈ ΡΡΡΠ΅ΡΡΠΎΠ²ΡΠΌ ΡΠΈΡΡΠ°ΡΠΈΡΠΌ.
Π‘Π»ΠΈΡΠΊΠΎΠΌ ΠΌΠ½ΠΎΠ³ΠΎ ΠΏΠ»ΡΡΠΎΠ², ΡΡΠΎΠ±Ρ ΡΠΊΠ°Π·Π°ΡΡ Π½Π΅Ρ. Π― Π³ΠΎΠ²ΠΎΡΡ Π΄Π° ΠΈ Π»ΠΎΠΆΡΡΡ Π½Π° ΠΊΡΡΠ΅ΡΠΊΡ. ΠΠΎΠΊΡΠΎΡ Π‘ΠΎΠ±ΠΎΠ»Π΅Π²Π° ΠΏΡΠΎΠΏΠΈΡΡΠ²Π°Π΅Ρ ΠΌΠ½Π΅ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΡ ΡΠ°Π·ΠΎΠ²ΡΡ Π΄ΠΎΠ·Ρ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ» (Π΄Π²Π΅ Π°ΠΌΠΏΡΠ»Ρ ΠΏΠΎ 2 ΠΌΠ»). ΠΡΠ΅Π³ΠΎ ΡΡΠΈ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΈΡΡ β Π΄Π»Ρ ΠΎΠ·Π½Π°ΠΊΠΎΠΌΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π»ΠΈ. ΠΠΎΠ»Π½ΡΠΉ ΠΊΡΡΡ Π² ΡΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ΅Π»ΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅Ρ Π΄Π΅ΡΡΡΡ ΠΏΡΠΎΡΠ΅Π΄ΡΡ Ρ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΈΡΠ½ΠΎΡΡΡΡ Π΄Π²Π°-ΡΡΠΈ ΡΠ°Π·Π° Π² Π½Π΅Π΄Π΅Π»Ρ, Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΎ 4β10 ΠΌΠ» (Π΄Π²Π΅-ΠΏΡΡΡ Π°ΠΌΠΏΡΠ») Π½Π° 250 ΠΌΠ» ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° ΠΈΠ»ΠΈ ΠΆΠ΅ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΡΠ½ΠΊΡΡΡΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ β 8β12 ΠΏΡΠΎΡΠ΅Π΄ΡΡ Ρ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΈΡΠ½ΠΎΡΡΡΡ ΠΎΠ΄ΠΈΠ½-Π΄Π²Π° ΡΠ°Π·Π° Π² Π½Π΅Π΄Π΅Π»Ρ.
ΠΠΎΠ²ΡΠΎΡΡΡΡ ΠΊΡΡΡ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ»-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ΅ΡΡΡ ΠΎΠ΄ΠΈΠ½-Π΄Π²Π° ΡΠ°Π·Π° Π² Π³ΠΎΠ΄. Π Π»ΡΡΡΠ΅ Π²ΡΠ΅Π³ΠΎ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄Ρ Π²ΡΠΏΡΡΠ΅ΠΊ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, ΠΏΡΠΈ ΠΎΠ±ΡΠ΅ΠΌ ΠΎΡΠ»Π°Π±Π»Π΅Π½ΠΈΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ°, Π²ΠΎ Π²ΡΠ΅ΠΌΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΡΡΠ΅ΡΡΠΎΠ²ΡΡ ΡΠΈΡΡΠ°ΡΠΈΠΉ, ΠΏΡΠΈ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ°Π»ΠΎΡΡΠΈ, Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠ΅ ΡΠ½Π° ΠΈ Ρ.Π΄.
Β«βΠΠ°Π΅Π½Π½Π΅ΠΊβ ΠΊΠΎΠ»ΡΡ ΠΈ Π² Π»ΠΈΡΠΎ, β Π³ΠΎΠ²ΠΎΡΠΈΡ Π²ΡΠ°Ρ-ΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³ ΠΠ²Π³Π΅Π½ΠΈΡ Π‘ΠΎΠ±ΠΎΠ»Π΅Π²Π°. β ΠΠ½ΡΡΡΠΈΠΌΡΡΠ΅ΡΠ½ΠΎ ΠΏΠΎ Π»ΠΈΡΡΠΈΠ½Π³ΠΎΠ²ΡΠΌ ΡΠΎΡΠΊΠ°ΠΌ Π΄Π»Ρ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ Π² ΠΌΡΡΡΠ°Ρ ΠΈ Π² ΠΏΠΎΠ΄ΠΊΠΎΠΆΠ½ΠΎ-ΠΆΠΈΡΠΎΠ²ΠΎΠΉ ΠΊΠ»Π΅ΡΡΠ°ΡΠΊΠ΅. ΠΠ° ΡΡΠ΅Ρ ΡΡΠΎΠ³ΠΎ ΠΌΡΡΡΡ Π½Π°ΡΠΈΠ½Π°ΡΡ Π»ΡΡΡΠ΅ ΡΠ°Π±ΠΎΡΠ°ΡΡ, ΡΠ»ΡΡΡΠ°Π΅ΡΡΡ ΡΠΎΠ½ΡΡ ΠΈ ΡΠ²Π΅Ρ Π»ΠΈΡΠ°. ΠΠ»Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ Π»ΠΈΡΡΠΈΠ½Π³-ΡΡΡΠ΅ΠΊΡΠ° ΠΏΠΎΡΡΠ΅Π±ΡΠ΅ΡΡΡ Π²ΠΎΡΠ΅ΠΌΡ-Π΄Π΅ΡΡΡΡ ΠΏΡΠΎΡΠ΅Π΄ΡΡ Ρ Π΄Π²ΡΠΌΡ Π°ΠΌΠΏΡΠ»Π°ΠΌΠΈ Π½Π° ΠΊΠ°ΠΆΠ΄ΡΡ. ΠΡΠΈ ΡΠ΅ΡΡΠ΅Π·Π½ΡΡ ΠΊΠΎΠΆΠ½ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°Ρ (Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ΅ ΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π΅) ΠΏΠΎΡΡΠ΅Π±ΡΠ΅ΡΡΡ ΡΠΆΠ΅ ΠΏΡΡΡ Π°ΠΌΠΏΡΠ» Π½Π° ΠΎΠ΄ΠΈΠ½ ΡΠ΅Π°Π½ΡΒ».
ΠΠ°ΠΏΠ΅Π»ΡΠ½ΠΈΡΡ ΠΌΠ½Π΅ ΡΡΠ°Π²ΠΈΡ ΠΊΠΎΡΠΌΠ΅ΡΠΎΠ»ΠΎΠ³-ΡΡΡΠ΅ΡΠΈΡΡ Π¦ΠΠΠ Π½Π° Π‘ΠΏΠΈΡΠΈΠ΄ΠΎΠ½ΠΎΠ²ΠΊΠ΅ ΠΠΊΠ°ΡΠ΅ΡΠΈΠ½Π° Π―ΠΊΡΠ½ΠΈΠ½Π°. Β«ΠΠΈΠΊΠ°ΠΊΠΈΡ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΠΉ ΠΏΠΎΡΠ»Π΅ ΠΏΡΠΎΡΠ΅Π΄ΡΡΡ Π½Π΅Ρ, Π½ΠΎ Π΄Π»Ρ Π»ΡΡΡΠ΅Π³ΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ° ΠΏΠ΅ΡΠ΅Π½Ρ Π»ΡΡΡΠ΅ Π½Π΅ ΠΏΠ΅ΡΠ΅Π³ΡΡΠΆΠ°ΡΡ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΏΠΈΡΠ΅ΠΉ ΠΈ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Π΅ΠΌ, β ΡΠΎΠ²Π΅ΡΡΠ΅Ρ ΠΎΠ½Π°. β Π ΡΡΠΎ Π΅ΡΠ΅ Ρ ΠΎΡΠΎΡΠΎ, βΠΠ°Π΅Π½Π½Π΅ΠΊβ Π½Π΅ Π΄Π°Π΅Ρ ΠΏΠΎΡΠ»Π΅ ΠΏΠ΅ΡΠ²ΡΡ ΠΏΡΠΎΡΠ΅Π΄ΡΡ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΡΠ΅ΠΊ, ΠΊΠ°ΠΊ ΡΡΠΎ Π±ΡΠ²Π°Π΅Ρ ΠΏΡΠΈ Π΄ΡΡΠ³ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠΈΡΡ Ρ Π½Π°ΠΊΠΎΠΏΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ. Π ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ β Π±ΠΎΠ΄ΡΠΎΡΡΡ, ΡΠ½Π΅ΡΠ³ΠΈΡΠ½ΠΎΡΡΡ, ΠΏΡΠΈΠ»ΠΈΠ² ΡΠΈΠ» β Π²Ρ Π·Π°ΠΌΠ΅ΡΠΈΡΠ΅ ΠΎΡΠ΅Π½Ρ ΡΠΊΠΎΡΠΎΒ».
ΠΠΎΡΠ»Π΅ ΠΏΠ΅ΡΠ²ΠΎΠΉ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΈΡΡ Ρ ΠΏΡΠΈΡΠ»ΡΡΠΈΠ²Π°ΡΡΡ ΠΊ ΡΠ²ΠΎΠΈΠΌ ΠΎΡΡΡΠ΅Π½ΠΈΡΠΌ β Π²ΡΠΎΠ΄Π΅ Π²ΡΠ΅ ΠΊΠ°ΠΊ ΠΎΠ±ΡΡΠ½ΠΎ, Π³ΠΎΠ»ΠΎΠ²Π° Π½Π΅ ΠΊΡΡΠΆΠΈΡΡΡ, Π½Π΅ ΡΠΎΡΠ½ΠΈΡ, Π² ΡΠΎΠ½ Π½Π΅ ΠΊΠ»ΠΎΠ½ΠΈΡ. ΠΠΎ ΠΈ ΡΡΠΏΠ΅ΡΡΠ½Π΅ΡΠ³ΠΈΠΈ Π½Π΅Ρ.
Π’ΠΎΠ»ΡΠΊΠΎ ΡΠ΅ΡΠ΅Π· ΡΡΠΈ ΠΏΡΠΎΡΠ΅Π΄ΡΡΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠ°ΡΡΡΠ½ΡΠ»ΠΈΡΡ Π½Π° ΡΡΠΈ Π½Π΅Π΄Π΅Π»ΠΈ, Ρ Π·Π°ΠΌΠ΅ΡΠ°Ρ ΠΎΠ±Π΅ΡΠ°Π½Π½ΡΠΉ ΠΏΡΠΈΠ»ΠΈΠ² ΡΠΈΠ» ΠΈ ΡΠ°Π±ΠΎΡΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ. ΠΠ»Ρ ΡΠ΅ΡΠ΅Π΄ΠΈΠ½Ρ Π·ΠΈΠΌΡ ΡΠΎΠ²Π΅ΡΡΠ΅Π½Π½ΠΎ Π½Π΅ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠ΅.
Π― ΡΠ°ΠΊΠΆΠ΅ Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΈΠ· Π²ΡΠ΅ΠΉ ΡΠ΅Π΄Π°ΠΊΡΠΈΠΈ, ΠΊΡΠΎ Π½Π΅ ΡΠ²Π°Π»ΠΈΠ»ΡΡ Ρ ΠΏΡΠΎΡΡΡΠ΄ΠΎΠΉ Π² Π½Π°ΡΠ°Π»Π΅ ΡΠ΅Π²ΡΠ°Π»Ρ, Ρ ΠΎΡΡ Π½ΠΈΠΊΠΎΠ³Π΄Π° Π½Π΅ ΠΌΠΎΠ³Π»Π° ΠΏΠΎΡ Π²Π°ΡΡΠ°ΡΡΡΡ ΠΊΡΠ΅ΠΏΠΊΠΈΠΌ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠΎΠΌ. Π Π·Π΅ΡΠΊΠ°Π»Π΅ ΠΎΡΠΎΠ±ΡΡ ΠΏΠ΅ΡΠ΅ΠΌΠ΅Π½ Π½Π΅ Π²ΠΈΠ΄Π½ΠΎ β Π²ΡΡΡΠΏΠ°Π½ΠΈΡ Π½Π° ΠΊΠΎΠΆΠ΅ Π²ΡΠ΅ ΡΠ°ΠΊ ΠΆΠ΅ ΠΏΠΎ Π³ΡΠ°ΡΠΈΠΊΡ (ΡΠΎ Π΅ΡΡΡ ΠΏΡΠΈ Π°ΠΊΠ½Π΅ Π²Π°ΠΌ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ» Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½Π΅ ΠΏΠΎΠΌΠΎΠΆΠ΅Ρ), Π½ΠΎΡΠΎΠ³ΡΠ±ΠΊΠ° Π½Π° ΠΌΠ΅ΡΡΠ΅, Π»ΠΈΡΡΠΈΠ½Π³-ΡΡΡΠ΅ΠΊΡ Π½Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½. ΠΠ°ΡΠΎ ΡΠΏΠ»Ρ ΠΊΠ°ΠΊ ΠΌΠ»Π°Π΄Π΅Π½Π΅Ρ, Π±Π»Π°Π³ΠΎΠΏΠΎΠ»ΡΡΠ½ΠΎ ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΉ Π² ΡΡΠΎΠΊ Π·Π΄ΠΎΡΠΎΠ²ΠΎΠΉ ΠΌΠ°ΡΠ΅ΡΡΡ, Π½ΠΈΠΊΠΎΠ³Π΄Π° Π½Π΅ Π²ΡΠ΅Π·ΠΆΠ°Π²ΡΠ΅ΠΉ ΠΈΠ· Π―ΠΏΠΎΠ½ΠΈΠΈ.
ΠΡΠ±ΠΎΠΏΡΡΠ½ΠΎ, ΡΡΠΎ ΠΆΠ΅ Π±ΡΠ΄Π΅Ρ, Π΅ΡΠ»ΠΈ ΠΏΡΠΎΠΉΡΠΈ Π²Π΅ΡΡ ΠΊΡΡΡ Π΄ΠΎ ΠΊΠΎΠ½ΡΠ°?
ΠΠ°ΠΊΠΈΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ ΡΠΊΡΡΡΠ°ΠΊΡ ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ, ΡΡΠΎ Π½Π΅ ΡΠ°ΠΊ Ρ ΠΏΡΠΈΠ΅ΠΌΠΎΠΌ Π±Π΅Π»ΠΊΠΎΠ²ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ² Π²Π½ΡΡΡΡ Π² Π²ΠΈΠ΄Π΅ ΡΠ°ΡΡΠ²ΠΎΡΠ°, ΡΠ΅ΠΌ ΠΠ°Π΅Π½Π½Π΅ΠΊ Π»ΡΡΡΠ΅ Π¦Π΅ΡΠ΅Π±ΡΠΎΠ»ΠΈΠ·ΠΈΠ½Π° ΠΈ ΡΠΌΠΎΠΆΠ΅Ρ Π»ΠΈ ΠΎΠ½ ΡΠΏΠ°ΡΡΠΈ ΠΏΠ΅ΡΠ΅Π½Ρ, ΠΊΠ°ΠΊ ΠΎΠ±ΡΠ°ΡΠΈΡΡ Π²ΡΠΏΡΡΡ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ, Π·Π°Π»Π΅ΡΠΈΡΡ ΡΠ°Π½Ρ ΠΈ Π·Π°Π±ΡΡΡ ΠΎ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ°Π»ΠΎΡΡΠΈ, ΡΠ°ΡΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Indicator.Ru Π² ΡΡΠ±ΡΠΈΠΊΠ΅ Β«Π§Π΅ΠΌ Π½Π°Ρ Π»Π΅ΡΠ°ΡΒ».
ΠΠ°Π΅Π½Π½Π΅ΠΊ β Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ. Π‘ΠΏΠΈΡΠΎΠΊ Π΅Π³ΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ ΠΊ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²ΠΏΠ΅ΡΠ°ΡΠ»ΡΠ΅Ρ:
β ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΠ°Π½Ρ ΠΈ ΡΡΠ±ΡΡ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΈ ΡΠ»Π΅Π΄Ρ ΠΏΠΎΡΠ»Π΅ Π°ΠΊΠ½Π΅;
β Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈΠ·-Π·Π° Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ ΠΈ Π²ΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ°;
β Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ°Π»ΠΎΡΡΡ;
β Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠ΅ ΠΈ Π½Π΅ΡΠ΄Π°ΡΠ½ΡΠ΅ ΠΠΠ;
β ΠΊΠ»ΠΈΠΌΠ°ΠΊΡ;
β Β«ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ°Β»;
β Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΈ Π³Π΅ΡΠΏΠ΅Ρ;
β ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΡΡΠ°ΡΠ΅Π½ΠΈΡ ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ;
ΠΠΎ ΡΠ°ΠΊ Π»ΠΈ ΠΎΠΏΡΠ°Π²Π΄Π°Π½ΠΎ ΡΠ°ΠΊΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ?
Π ΡΠΏΠΈΡΠΊΠ°Ρ (Π½Π΅) Π·Π½Π°ΡΠΈΠ»ΡΡ
ΠΡ ΡΠΆΠ΅ Π½Π΅ ΡΠ°Π· ΡΡΠ°Π»ΠΊΠΈΠ²Π°Π»ΠΈΡΡ Ρ ΠΏΡΠΈΠΌΠ΅ΡΠ°ΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»ΠΈ ΠΊΠΎΡΠΎΡΡΡ ΠΏΡΠΈ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅ ΡΠ΅Π³Π°Π»ΠΈΠΉ (Π½Π°Π»ΠΈΡΠΈΠΈ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ ΠΈ Π΄Π°ΠΆΠ΅ Π½Π°Π³ΡΠ°Π΄ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ ΡΡΡΠ°Π½ Π‘ΠΠ) Π²ΡΠ΅ Π΅ΡΠ΅ Π½Π΅ ΠΌΠΎΠ³ΡΡ Π΄ΠΎΠΊΠ°Π·Π°ΡΡ ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ. Π ΠΠΎΡΡΠ΅Π΅ΡΡΡΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² ΡΠΏΠΎΠΌΡΠ½ΡΡΠΎ ΡΠΎΠ»ΡΠΊΠΎ Π΄Π²Π° Π΅Π³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ 2008 Π³ΠΎΠ΄Π°. ΠΠ½ΠΈ Π΄ΠΎΠ»ΠΆΠ½Ρ Π±ΡΠ»ΠΈ ΠΎΠΊΠΎΠ½ΡΠΈΡΡΡΡ Π² 2009 Π³ΠΎΠ΄Ρ (ΠΏΠΎΡΡΠΈ Π΄Π΅ΡΡΡΡ Π»Π΅Ρ Π½Π°Π·Π°Π΄), Π½ΠΎ Π΄ΠΎ ΡΠΈΡ ΠΏΠΎΡ Π½Π΅ Π·Π°Π²Π΅ΡΡΠ΅Π½Ρ. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΡΠΎ, Π² 2008 Π³ΠΎΠ΄Ρ Π»Π΅ΠΊΠ°ΡΡΡΠ²ΠΎ Π±ΡΠ»ΠΎ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΠΈ ΡΡΠΏΠ΅ΡΠ½ΠΎ ΠΏΡΠΎΡΠ»ΠΎ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΏΠ΅ΡΠ΅ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΉ.
Π Π²ΠΎΡ Π½Π° ΡΠ°ΠΉΡΠ΅ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠ³ΠΎ Π°Π³Π΅Π½ΡΡΡΠ²Π° ΠΏΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌ ΡΡΠ΅Π΄ΡΡΠ²Π°ΠΌ Π½Π΅Ρ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΎ ΠΏΠΎΠ΄ΠΎΠ±Π½ΠΎΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ΅. ΠΠ΅Ρ ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½ΠΈΡ Ρ ΡΠΊΡΡΡΠ°ΠΊΡΠ° ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΠΈ ΠΎΡ Π°ΠΌΠ΅ΡΠΈΠΊΠ°Π½ΡΠΊΠΎΠ³ΠΎ Π£ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΏΠΎ ΡΠ°Π½ΠΈΡΠ°ΡΠ½ΠΎΠΌΡ Π½Π°Π΄Π·ΠΎΡΡ Π·Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² ΠΈ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ² (Food and Drug Administration, FDA).
ΠΠ° Π²ΠΊΠ»Π°Π΄ΠΊΠ΅ Β«ΠΠ½Π΅Π½ΠΈΡ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ²Β» ΠΎΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΉΡΠ° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΌΠΎΠΆΠ½ΠΎ Π½Π°ΠΉΡΠΈ ΠΏΠΎΡΡΠΈ ΡΡΠΈ Π΄Π΅ΡΡΡΠΊΠ° Π²ΠΈΠ΄Π΅ΠΎ β ΠΎΡΠ·ΡΠ²ΠΎΠ² ΠΎΡ Π²ΡΠ°ΡΠ΅ΠΉ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π΄ΠΎΠΊΡΠΎΡΠΎΠ² ΠΈ ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠΎΠ² Π½Π°ΡΠΊ. Π£ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ ΠΈΠ· Π½ΠΈΡ ΠΎΡΠΊΡΡΡΠΎ ΡΠΊΠ°Π·Π°Π½Π° Π°ΡΡΠΈΠ»ΠΈΠ°ΡΠΈΡ Ρ ΠΊΠΎΡΠΏΠΎΡΠ°ΡΠΈΠ΅ΠΉ-ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΌ (RHANA). ΠΠΏΡΠΎΡΠ΅ΠΌ, Π²ΡΠ΅ ΡΠΎΠ»ΠΈΠΊΠΈ ΡΠ½ΡΡΡ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠ΅ΠΉ-ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΌ, ΡΠ°ΠΊ ΡΡΠΎ, Π΄Π°ΠΆΠ΅ Π΅ΡΠ»ΠΈ Π²ΡΡΠΊΠ°Π·Π°Π²ΡΠΈΠΉΡΡ ΠΊ Π½Π΅ΠΉ ΠΎΡΠΊΡΡΡΠΎ Π½Π΅ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ, ΠΊΠΎΠ½ΡΠ»ΠΈΠΊΡ ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠΎΠ² Π½Π°Π»ΠΈΡΠΎ. ΠΠ½ΠΎΠ³ΠΈΠ΅ ΡΠΎΠ»ΠΈΠΊΠΈ ΠΎΡΠΊΡΠΎΠ²Π΅Π½Π½ΠΎ ΡΠ΅ΠΊΠ»Π°ΠΌΠ½ΡΠ΅: ΡΠ½Π°ΡΠ°Π»Π° Π³ΠΎΠ²ΠΎΡΠΈΡΡΡ ΠΎ ΡΠΎΠΌ, ΠΊΠ°ΠΊ Π²Π°ΠΆΠ½ΠΎ ΡΠΎΡ ΡΠ°Π½ΡΡΡ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅, Π½Π°ΡΠΈΠ½Π°Ρ Ρ ΡΠΎΠΆΠ΄Π΅Π½ΠΈΡ, ΡΠ°ΡΡΠΊΠ°Π·ΡΠ²Π°Π΅ΡΡΡ ΠΎΠ± ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡΡ ΠΆΠΈΠ·Π½ΠΈ Π² ΡΡΡΠ΅ΡΡΠ΅ ΠΈ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΈ, ΠΏΠΎΡΠΎΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΏΡΠ΅ΠΏΠΎΠ΄Π½ΠΎΡΠΈΡΡΡ ΠΊΠ°ΠΊ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅.
ΠΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π°ΡΠ³ΡΠΌΠ΅Π½Ρ ΠΏΠΎΠ»Π΅Π·Π½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π² ΡΠΎΠΌ, ΡΡΠΎ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ° Π΄Π°Π΅Ρ ΠΆΠΈΠ·Π½Ρ Π½ΠΎΠ²ΠΎΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΡ (Π° Π·Π½Π°ΡΠΈΡ, ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ ΠΏΠΎΠ»Π΅Π·Π½ΡΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°), ΡΡΠΎ ΠΎΠ½Π° Β«ΡΠ°ΠΌΠΎΠ΅ ΡΠΎΠΊΡΠΎΠ²Π΅Π½Π½ΠΎΠ΅Β» ΠΈ Β«ΡΠ°ΠΌΡΠΉ Π²Π°ΠΆΠ½ΡΠΉ ΠΎΡΠ³Π°Π½ Π² ΡΠ΅Π»Π΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΆΠ΅Π½ΡΠΈΠ½ΡΒ». ΠΠ΄Π½Π°ΠΊΠΎ ΡΡΠΎ Π½Π°ΠΏΠΎΠΌΠΈΠ½Π°Π΅Ρ ΡΡΡΠ°ΡΠ΅Π²ΡΠΈΠ΅ Π²Π΅ΠΊΠ° Π½Π°Π·Π°Π΄ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ Π²Π°Π½Π½Π° Ρ ΠΊΡΠΎΠ²ΡΡ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΡΡ ΠΌΠ»Π°Π΄Π΅Π½ΡΠ΅Π² ΠΎΠΌΠΎΠ»Π°ΠΆΠΈΠ²Π°Π΅Ρ ΠΊΠΎΠΆΡ, Π° ΠΏΠ΅ΡΠ΅Π»ΠΈΠ²Π°Π½ΠΈΠ΅ Β«ΠΌΠΎΠ»ΠΎΠ΄ΠΎΠΉΒ» ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ΄Π»Π΅Π²Π°Π΅Ρ ΠΆΠΈΠ·Π½Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ°. Π ΠΊΡΠΎΠ²ΠΈ ΡΠΎΠΆΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠΈΡΡΡ ΠΎΠ³ΡΠΎΠΌΠ½ΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠΎΠ»Π΅Π·Π½ΡΡ Π²Π΅ΡΠ΅ΡΡΠ². ΠΠΎ Π²ΡΡΠ΄ Π»ΠΈ ΠΊΡΠΎ-ΡΠΎ ΡΡΠ°Π½Π΅Ρ ΠΏΡΠΈΡΠ°Π²Π½ΠΈΠ²Π°ΡΡ ΠΏΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΡΡΠ΅Π²Π΅ΡΠΈΡ Π² Π΄ΡΡ Π΅ ΠΠ»ΠΈΠ·Π°Π²Π΅ΡΡ ΠΠ°ΡΠΎΡΠΈ ΠΊ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡΠΌ.
ΠΠ΅ Π±ΡΠ΄Π΅ΠΌ ΡΠΏΠ΅ΡΠΈΡΡ ΠΈ Ρ ΠΠ°Π΅Π½Π½Π΅ΠΊΠΎΠΌ: Π΄Π°ΠΆΠ΅ Π΅ΡΠ»ΠΈ Π½Π΅ ΠΎΠ±ΡΠ°ΡΠ°ΡΡ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ Π½Π° ΡΠ²Π½ΡΠΉ ΡΠ΅ΠΊΠ»Π°ΠΌΠ½ΡΠΉ ΠΏΠΎΡΡΠ», Π² ΡΠ°ΠΌΠΊΠ°Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΌΠ½Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ², ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎΠ΅ Π½Π° ΠΎΠΏΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ ΠΈ Π»ΠΈΡΠ½ΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅, ΡΡΠΈΡΠ°Π΅ΡΡΡ ΡΠ°ΠΌΡΠΌ Π½ΠΈΠ·ΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ. ΠΠΎ ΡΠ΅ΠΊΠ»Π°ΠΌΠ½ΡΠ΅ ΡΠΎΠ»ΠΈΠΊΠΈ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΡΠ°ΡΡΡΠΈΡΠ°Π½Ρ Π½Π° ΡΡΠ΅Π΄Π½Π΅ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΠΊΡΠΏΠ°ΡΠ΅Π»Ρ, ΠΊΠΎΡΠΎΡΡΠΉ Π½Π΅ ΡΠ°Π·Π±ΠΈΡΠ°Π΅ΡΡΡ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅. Π ΠΌΡ Π»ΡΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠΈΠΌ, ΡΡΠΎ ΠΆΠ΅ Π²Ρ ΠΎΠ΄ΠΈΡ Π² ΡΠΎΡΡΠ°Π² ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.
Π‘ΡΡΠ΅ΡΡΠ²ΡΡΡ ΠΎΡΠ΅Π½Ρ Π»ΡΠ±ΠΎΠΏΡΡΠ½ΡΠ΅ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠ΅ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ, Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, Π½Π°Π²ΡΠ·ΡΠΈΠ²ΠΎΠ΅ Π·Π°Π³Π»Π°ΡΡΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄ΠΌΠ΅ΡΠΎΠ². Π ΠΆΠ΅Π»ΡΠ΄ΠΊΠ΅ ΠΎΠ΄Π½ΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ, ΡΡΡΠ°Π΄Π°ΡΡΠ΅ΠΉ ΠΎΡ ΡΡΠΎΠΉ ΠΌΠ°Π½ΠΈΠΈ, Π±ΡΠ»ΠΎ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ 2500 ΠΈΠ½ΠΎΡΠΎΠ΄Π½ΡΡ ΠΏΡΠ΅Π΄ΠΌΠ΅ΡΠΎΠ².
74-Π»Π΅ΡΠ½ΠΈΠΉ ΠΆΠΈΡΠ΅Π»Ρ ΠΠ²ΡΡΡΠ°Π»ΠΈΠΈ ΠΠΆΠ΅ΠΉΠΌΡ Π₯Π°ΡΡΠΈΡΠΎΠ½ ΡΡΠ°Π½ΠΎΠ²ΠΈΠ»ΡΡ Π΄ΠΎΠ½ΠΎΡΠΎΠΌ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΊΠΎΠ»ΠΎ 1000 ΡΠ°Π·. Π£ Π½Π΅Π³ΠΎ ΡΠ΅Π΄ΠΊΠ°Ρ Π³ΡΡΠΏΠΏΠ° ΠΊΡΠΎΠ²ΠΈ, Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊΠΎΡΠΎΡΠΎΠΉ ΠΏΠΎΠΌΠΎΠ³Π°ΡΡ Π²ΡΠΆΠΈΡΡ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌ Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π°Π½Π΅ΠΌΠΈΠΈ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π°Π²ΡΡΡΠ°Π»ΠΈΠ΅Ρ ΡΠΏΠ°Ρ ΠΎΠΊΠΎΠ»ΠΎ Π΄Π²ΡΡ ΠΌΠΈΠ»Π»ΠΈΠΎΠ½ΠΎΠ² Π΄Π΅ΡΠ΅ΠΉ.
ΠΡΠΎΠΌΠ΅ Π»ΡΠ΄Π΅ΠΉ, ΠΎΡ ΠΏΡΠΎΡΡΠ°ΡΠΈΡΠ° ΡΡΡΠ°Π΄Π°Π΅Ρ Π²ΡΠ΅Π³ΠΎ ΠΎΠ΄Π½ΠΎ ΠΆΠΈΠ²ΠΎΠ΅ ΡΡΡΠ΅ΡΡΠ²ΠΎ Π½Π° ΠΏΠ»Π°Π½Π΅ΡΠ΅ ΠΠ΅ΠΌΠ»Ρ β ΡΠΎΠ±Π°ΠΊΠΈ. ΠΠΎΡ ΡΠΆ Π΄Π΅ΠΉΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½Π°ΡΠΈ ΡΠ°ΠΌΡΠ΅ Π²Π΅ΡΠ½ΡΠ΅ Π΄ΡΡΠ·ΡΡ.
ΠΠΎΠ³Π΄Π° Π²Π»ΡΠ±Π»Π΅Π½Π½ΡΠ΅ ΡΠ΅Π»ΡΡΡΡΡ, ΠΊΠ°ΠΆΠ΄ΡΠΉ ΠΈΠ· Π½ΠΈΡ ΡΠ΅ΡΡΠ΅Ρ 6,4 ΠΊΠΊΠ°Π»ΠΎΡΠΈΠΉ Π² ΠΌΠΈΠ½ΡΡΡ, Π½ΠΎ ΠΏΡΠΈ ΡΡΠΎΠΌ ΠΎΠ½ΠΈ ΠΎΠ±ΠΌΠ΅Π½ΠΈΠ²Π°ΡΡΡΡ ΠΏΠΎΡΡΠΈ 300 Π²ΠΈΠ΄Π°ΠΌΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠΉ.
ΠΡΠ»ΠΈ Π±Ρ Π²Π°ΡΠ° ΠΏΠ΅ΡΠ΅Π½Ρ ΠΏΠ΅ΡΠ΅ΡΡΠ°Π»Π° ΡΠ°Π±ΠΎΡΠ°ΡΡ, ΡΠΌΠ΅ΡΡΡ Π½Π°ΡΡΡΠΏΠΈΠ»Π° Π±Ρ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠΎΠΊ.
Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΠΌ, ΠΆΠ΅Π½ΡΠΈΠ½Ρ, Π²ΡΠΏΠΈΠ²Π°ΡΡΠΈΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΡΡΠ°ΠΊΠ°Π½ΠΎΠ² ΠΏΠΈΠ²Π° ΠΈΠ»ΠΈ Π²ΠΈΠ½Π° Π² Π½Π΅Π΄Π΅Π»Ρ, ΠΈΠΌΠ΅ΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΡΠΈΡΠΊ Π·Π°Π±ΠΎΠ»Π΅ΡΡ ΡΠ°ΠΊΠΎΠΌ Π³ΡΡΠ΄ΠΈ.
ΠΠ΅ΡΠ΅Π½Ρ β ΡΡΠΎ ΡΠ°ΠΌΡΠΉ ΡΡΠΆΠ΅Π»ΡΠΉ ΠΎΡΠ³Π°Π½ Π² Π½Π°ΡΠ΅ΠΌ ΡΠ΅Π»Π΅. ΠΠ΅ ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²Π΅Ρ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 1,5 ΠΊΠ³.
ΠΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ΅, ΠΏΠΎ ΠΏΠΎΠ½Π΅Π΄Π΅Π»ΡΠ½ΠΈΠΊΠ°ΠΌ ΡΠΈΡΠΊ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΡΠ°Π²ΠΌ ΡΠΏΠΈΠ½Ρ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ Π½Π° 25%, Π° ΡΠΈΡΠΊ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΡΡΡΠΏΠ° β Π½Π° 33%. ΠΡΠ΄ΡΡΠ΅ ΠΎΡΡΠΎΡΠΎΠΆΠ½Ρ.
ΠΡΠ΄ΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠΈΠ²ΡΠΊΠ»ΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎ Π·Π°Π²ΡΡΠ°ΠΊΠ°ΡΡ, Π³ΠΎΡΠ°Π·Π΄ΠΎ ΡΠ΅ΠΆΠ΅ ΡΡΡΠ°Π΄Π°ΡΡ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ.
Π‘ΡΠΎΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈ ΠΏΠΎΡΠ²ΠΈΠ»ΠΈΡΡ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½Π΅Π΄Π°Π²Π½ΠΎ. ΠΡΠ΅ Π² 19 Π²Π΅ΠΊΠ΅ Π²ΡΡΡΠ²Π°ΡΡ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Π·ΡΠ±Ρ Π²Ρ ΠΎΠ΄ΠΈΠ»ΠΎ Π² ΠΎΠ±ΡΠ·Π°Π½Π½ΠΎΡΡΠΈ ΠΎΠ±ΡΡΠ½ΠΎΠ³ΠΎ ΠΏΠ°ΡΠΈΠΊΠΌΠ°Ρ Π΅ΡΠ°.
ΠΠ»Ρ ΡΠΎΠ³ΠΎ ΡΡΠΎΠ±Ρ ΡΠΊΠ°Π·Π°ΡΡ Π΄Π°ΠΆΠ΅ ΡΠ°ΠΌΡΠ΅ ΠΊΠΎΡΠΎΡΠΊΠΈΠ΅ ΠΈ ΠΏΡΠΎΡΡΡΠ΅ ΡΠ»ΠΎΠ²Π°, ΠΌΡ Π·Π°Π΄Π΅ΠΉΡΡΠ²ΡΠ΅ΠΌ 72 ΠΌΡΡΡΡ.
ΠΡΠΎΠ²Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Β«Π±Π΅Π³Π°Π΅ΡΒ» ΠΏΠΎ ΡΠΎΡΡΠ΄Π°ΠΌ ΠΏΠΎΠ΄ ΠΎΠ³ΡΠΎΠΌΠ½ΡΠΌ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΈ ΠΏΡΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΈ ΠΈΡ ΡΠ΅Π»ΠΎΡΡΠ½ΠΎΡΡΠΈ ΡΠΏΠΎΡΠΎΠ±Π½Π° Π²ΡΡΡΡΠ΅Π»ΠΈΡΡ Π½Π° ΡΠ°ΡΡΡΠΎΡΠ½ΠΈΠ΅ Π΄ΠΎ 10 ΠΌΠ΅ΡΡΠΎΠ².
ΠΡΠ»ΠΈ ΡΠ»ΡΠ±Π°ΡΡΡΡ Π²ΡΠ΅Π³ΠΎ Π΄Π²Π° ΡΠ°Π·Π° Π² Π΄Π΅Π½Ρ β ΠΌΠΎΠΆΠ½ΠΎ ΠΏΠΎΠ½ΠΈΠ·ΠΈΡΡ ΠΊΡΠΎΠ²ΡΠ½ΠΎΠ΅ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ ΠΈ ΡΠ½ΠΈΠ·ΠΈΡΡ ΡΠΈΡΠΊ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΠΈΠ½ΡΠ°ΡΠΊΡΠΎΠ² ΠΈ ΠΈΠ½ΡΡΠ»ΡΡΠΎΠ².
Π‘Π°ΠΌΠ°Ρ Π²ΡΡΠΎΠΊΠ°Ρ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠ° ΡΠ΅Π»Π° Π±ΡΠ»Π° Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π° Ρ Π£ΠΈΠ»Π»ΠΈ ΠΠΆΠΎΠ½ΡΠ° (Π‘Π¨Π), ΠΊΠΎΡΠΎΡΡΠΉ ΠΏΠΎΡΡΡΠΏΠΈΠ» Π² Π±ΠΎΠ»ΡΠ½ΠΈΡΡ Ρ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠΎΠΉ 46,5Β°C.
Π‘ΡΠ΅Π΄Π½ΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ Π»Π΅Π²ΡΠ΅ΠΉ ΠΌΠ΅Π½ΡΡΠ΅, ΡΠ΅ΠΌ ΠΏΡΠ°Π²ΡΠ΅ΠΉ.
ΠΡΡΠ΅ΡΠ΅Π³Π°ΠΉΡΠ΅ΡΡ ΠΏΠΎΠ΄Π΄Π΅Π»ΠΎΠΊ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠ°Π΅Π½Π½Π΅ΠΊ
ΠΡΠ΅ΠΌ Π·Π°ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠΎΠ²Π°Π½Π½ΡΠΌ Π»ΠΈΡΠ°ΠΌ
Π£Π²Π°ΠΆΠ°Π΅ΠΌΡΠ΅ Π³ΠΎΡΠΏΠΎΠ΄Π°!ΠΠΠ ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ ΠΠΎΡΠΏΠΎΡΠ°ΡΠΈΡ Β«Π ΠΠΠΒ» ΠΊΠ°ΠΊ ΡΠΊΡΠΊΠ»ΡΠ·ΠΈΠ²Π½ΡΠΉ Π΄ΠΈΡΡΡΠΈΠ±ΡΡΠΎΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π΄Π»Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Β«ΠΠ°Π΅Π½Π½Π΅ΠΊΒ» ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΈ Japan Bio Products Co., Ltd.» (JPB Π‘ΠΎ., Ltd.) (Π―ΠΏΠΎΠ½ΠΈΡ) Π² ΡΠΎΡΠΌΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠ° Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ (Π² Π°ΠΌΠΏΡΠ»Π°Ρ
ΠΏΠΎ 2 ΠΌΠ») ΠΈ Π΄Π΅ΡΠΆΠ°ΡΠ΅Π»Ρ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ΄ΠΎΡΡΠΎΠ²Π΅ΡΠ΅Π½ΠΈΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, ΡΠΎΠΎΠ±ΡΠ°Π΅Ρ, ΡΡΠΎ Ρ ΡΠ΅Π²ΡΠ°Π»Ρ 2019 Π³. ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π²Π²ΠΎΠ΄ΠΈΡ Π² ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ (β 10 ΠΈ β 50) Ρ Π½ΠΎΠ²ΡΠΌ ΠΎΡΠΎΡΠΌΠ»Π΅Π½ΠΈΠ΅ΠΌ; ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠ΅ΡΡ Π² ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ Π΄ΠΎΡΡΠ΅ Π½Π° Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ, ΡΠΎΠ³Π»Π°ΡΠΎΠ²Π°Π½Ρ ΠΈ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΠΠΈΠ½ΠΈΡΡΠ΅ΡΡΡΠ²ΠΎΠΌ ΠΠ΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π Π€ 08.10.2018 Π³.
Π ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΏ. 9 ΡΡ. 30 Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π·Π°ΠΊΠΎΠ½Π° ΠΎΡ 12 Π°ΠΏΡΠ΅Π»Ρ 2010 Π³. β 61-Π€Π Β«ΠΠ± ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ²Β» ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Ρ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠΈΠΌ ΠΎΡΠΎΡΠΌΠ»Π΅Π½ΠΈΠ΅ΠΌ Π΄ΠΎΠΏΡΡΡΠΈΠΌΠΎ Π΄ΠΎ ΠΈΡΡΠ΅ΡΠ΅Π½ΠΈΡ Π΅Π³ΠΎ ΡΡΠΎΠΊΠ° Π³ΠΎΠ΄Π½ΠΎΡΡΠΈ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊΠΎΠ³ΠΎ-ΡΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ Π Π€ Π² ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΈ Π±ΡΠ΄Π΅Ρ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΊΠ°ΠΊ Ρ Π½ΠΎΠ²ΡΠΌ ΠΎΡΠΎΡΠΌΠ»Π΅Π½ΠΈΠ΅ΠΌ, ΡΠ°ΠΊ ΠΈ Ρ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠΈΠΌ.
ΠΠ°ΡΠ°Π½ΡΠΈΡΠΌΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π΅Π³ΠΎ ΡΠΎΠ»ΡΠΊΠΎ Ρ ΠΠΠ ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ ΠΠΎΡΠΏΠΎΡΠ°ΡΠΈΡ Β«Π ΠΠΠΒ» ΠΈ Π΅Π³ΠΎ ΠΎΡΠΈΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ, ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ ΠΊΠΎΡΠΎΡΡΡ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° Π½Π° ΡΠ°ΠΉΡΠ°Ρ
ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΈ β http://laennec.ru, Π° ΡΠ°ΠΊΠΆΠ΅ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΈΡΠΌΠ΅Π½Π½ΠΎΠΉ ΡΡΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠΈ, ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠΉ Π΄Π»Ρ ΠΏΠΎΡΡΠ°Π²ΠΎΠΊ ΠΈ ΠΏΡΠΎΠ΄Π°ΠΆ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ Π Π€ ΠΈ ΡΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½ΠΎΠΉ ΠΠΠΠΠΠ ΠΠΠΠ Π ΠΠ‘Π‘ΠΠΠ‘ΠΠΠ Π€ΠΠΠΠ ΠΠ¦ΠΠ, Π½Π°Π»ΠΈΡΠΈΠ΅ Π·Π°ΡΠΈΡΠ½ΠΎΠΉ Π³ΠΎΠ»ΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π²ΡΠΊΡΡΡΠΈΡ, ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π½ΠΎΠΌΠ΅ΡΠ° ΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° (ΡΠΊΠ°Π·Π°Π½ Π½Π° ΠΎΠ±ΡΠ°ΡΠ½ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Π΅ ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠΈ, ΡΠΎΡ ΠΆΠ΅ Π½ΠΎΠΌΠ΅Ρ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½ Π½Π° ΠΊΠ°ΠΆΠ΄ΠΎΠΉ Π°ΠΌΠΏΡΠ»Π΅) ΠΈ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΎ Π΄ΠΈΡΡΡΠΈΠ±ΡΡΠΎΡΠ΅ (ΠΎΠ±ΡΠ·Π°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Π»ΠΎΠ³ΠΎΡΠΈΠΏΠ° RHANA). ΠΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΠΈ ΡΡΠ΅Π΄ΡΡΠ² Π΅Π΅ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΈ Π·Π°ΡΠΈΡΡ (ΠΊΠ°ΠΊ Ρ Π½ΠΎΠ²ΡΠΌ ΠΎΡΠΎΡΠΌΠ»Π΅Π½ΠΈΠ΅ΠΌ, ΡΠ°ΠΊ ΠΈ Ρ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠΈΠΌ) ΠΌΠΎΠΆΠ½ΠΎ ΠΏΡΠΎΠ²Π΅ΡΠΈΡΡ Π½Π° ΡΠ°ΠΉΡΠ΅ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΈ β http://laennec.ru, ΡΠΊΠ°Π·Π°Π² Π½ΠΎΠΌΠ΅Ρ ΡΠ΅ΡΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.
ΠΡΠ΅Π΄Π»Π°Π³Π°Π΅ΠΌΡΠ΅ ΠΊ ΠΏΡΠΎΠ΄Π°ΠΆΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Π² Π½Π΅ΡΡΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠ°Ρ
, ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° Π½Π΅ Π·Π°Π²ΠΎΠ΄Π° «Japan Bio Products Co., Ltd.» (JPB Π‘ΠΎ., Ltd.) (Π―ΠΏΠΎΠ½ΠΈΡ) ΡΠ²Π»ΡΡΡΡΡ, ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ, Π½Π΅Π»Π΅Π³Π°Π»ΡΠ½ΡΠΌΠΈ ΠΈ ΠΊΠΎΠ½ΡΡΠ°ΡΠ°ΠΊΡΠ½ΡΠΌΠΈ. ΠΠΈ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΡ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ, Π½ΠΈ Π΅Ρ ΡΠΊΡΠΊΠ»ΡΠ·ΠΈΠ²Π½ΡΠΉ Π΄ΠΈΡΡΡΠΈΠ±ΡΡΠΎΡ Π½Π΅ Π½Π΅ΡΡΡ ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΡΡΠΈ Π·Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π΄Π°Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ².
ΠΡΠ΄ΡΡΠ΅ ΠΎΡΡΠΎΡΠΎΠΆΠ½Ρ ΠΏΡΠΈ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½ΠΈΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ².
ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΠΏΠΎΡΠΊΠΎΠ»ΡΠΊΡ ΠΈΡΠΊΠ»ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠ°Π²ΠΎ Π½Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΠ²Π°ΡΠ½ΠΎΠ³ΠΎ Π·Π½Π°ΠΊΠ° ΠΠΠΠΠΠΠ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ ΡΡΠ»ΡΠ³, ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠΈΡ ΠΠΠ ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ ΠΠΎΡΠΏΠΎΡΠ°ΡΠΈΡ Β«Π ΠΠΠΒ» (ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎ Π½Π° ΡΠΎΠ²Π°ΡΠ½ΡΠΉ Π·Π½Π°ΠΊ β 552870), ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΊ ΠΏΡΠΎΠ΄Π°ΠΆΠ΅, ΠΏΡΠΎΠ΄Π°ΠΆΠ° ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π΄Π»Ρ ΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΡΡΠ»ΡΠ³ ΡΡΠ΅ΡΡΠΈΠΌΠΈ Π»ΠΈΡΠ°ΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠΠΠΠΠΠ ΠΈΠ»ΠΈ ΡΡ ΠΎΠ΄Π½ΡΡ Ρ Π½ΠΈΠΌ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½ΠΈΠΉ (LAENNEC, LAENEC, LAENNEK, ΠΠΠΠΠΠ ΠΈ Ρ.Π΄.) Π±Π΅Π· ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΡΠΊΠ»ΡΡΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΏΡΠ°Π² Π½Π° ΡΠΎΠ²Π°ΡΠ½ΡΠΉ Π·Π½Π°ΠΊ, Π·Π° ΠΊΠΎΡΠΎΡΠΎΠ΅ Π·Π°ΠΊΠΎΠ½ΠΎΠ΄Π°ΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠΌΠΎΡΡΠ΅Π½Π° ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΡΡΡ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠ³ΠΎΠ»ΠΎΠ²Π½Π°Ρ. ΠΠΎ ΠΈΠ·Π±Π΅ΠΆΠ°Π½ΠΈΠ΅ ΠΏΡΠ΅ΡΠ΅Π½Π·ΠΈΠΉ ΠΎ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΈ ΠΏΡΠ°Π² Π½Π° ΡΠΎΠ²Π°ΡΠ½ΡΠΉ Π·Π½Π°ΠΊ ΠΈΠ·Π±Π΅Π³Π°ΠΉΡΠ΅ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ½ΡΡΠ°ΡΠ°ΠΊΡΠ½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ².
Π Π½Π°Ρ Π΄Π΅ΡΠ°Π»ΡΠ½Π°Ρ
ΠΠΠ‘Π’Π Π£ΠΠ¦ΠΠ―
ΠΏΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π΄Π»Ρ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ
ΠΠΠΠΠΠΠ
Π Π΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ Π½ΠΎΠΌΠ΅Ρ: Π β013851/01
Π’ΠΎΡΠ³ΠΎΠ²ΠΎΠ΅ Π½Π°Π·Π²Π°Π½ΠΈΠ΅: ΠΠ°Π΅Π½Π½Π΅ΠΊ
ΠΠ΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠΎΡΠΌΠ°: ΡΠ°ΡΡΠ²ΠΎΡ Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ
Π‘ΠΎΡΡΠ°Π² Π 2 ΠΌΠ» ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠΎΠ΄Π΅ΡΠΆΠΈΡΡΡ Β112 ΠΌΠ³ Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°ΡΠ° ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, Π²ΠΎΠ΄Π° Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, ΠΊΠΎΡΡΠ΅ΠΊΡΠΎΡ ΡΠ (Π½Π°ΡΡΠΈΡ Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠ΄ ΠΈΠ»ΠΈ ΠΊΠΈΡΠ»ΠΎΡΠ° Ρ Π»ΠΎΡΠΈΡΡΠΎΠ²ΠΎΠ΄ΠΎΡΠΎΠ΄Π½Π°Ρ).
ΠΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΠΡΠΎΠ·ΡΠ°ΡΠ½Π°Ρ ΠΆΠΈΠ΄ΠΊΠΎΡΡΡ ΠΎΡ ΡΠ²Π΅ΡΠ»ΠΎ-ΠΆΠ΅Π»ΡΠΎΠ³ΠΎ Π΄ΠΎ ΠΊΠΎΡΠΈΡΠ½Π΅Π²ΠΎΠ³ΠΎ ΡΠ²Π΅ΡΠ° Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠΌ Π·Π°ΠΏΠ°Ρ ΠΎΠΌ.
Π€Π°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π³ΡΡΠΏΠΏΠ° ΠΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅Π΅ ΠΈ Π³Π΅ΠΏΠ°ΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡΠ½ΠΎΠ΅ ΡΡΠ΅Π΄ΡΡΠ²ΠΎ.
ΠΠΎΠ΄ ΠΠ’Π₯: L03, Π05ΠΠ
Π€Π°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΠ°Π΅Π½Π½Π΅ΠΊ ΠΏΡΠΎΡΠ²Π»ΡΠ΅Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π·Π° ΡΡΠ΅Ρ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΡΡΠΈΠΌΡΠ»ΠΈΡΠΎΠ²Π°ΡΡ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅Ρ ΠΈ ΠΏΠΎΠ²ΡΡΠ°ΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ°Π³ΠΎΡΠΈΡΠΎΠ² ΠΈ Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠΈΠ»Π»Π΅ΡΠΎΠ²; ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅Ρ Π±Π°ΠΊΡΠ΅ΡΠΈΡΠΈΠ΄Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ, ΠΏΡΠΎΡΠ²Π»ΡΡΡΡΡΡΡ Π² ΠΈΡ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΡΠ½ΠΈΡΡΠΎΠΆΠ°ΡΡ Π·Π°Ρ Π²Π°ΡΠ΅Π½Π½ΡΠΉ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ. Π¦ΠΈΡΠΎΠΊΠΈΠ½Ρ, Π²Ρ ΠΎΠ΄ΡΡΠΈΠ΅ Π² ΡΠΎΡΡΠ°Π² ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, Π°ΠΊΡΠΈΠ²ΠΈΠ·ΠΈΡΡΡΡ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΡΡ ΠΈ Π½Π°Π΄Π·ΠΎΡΠ½ΡΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠΎΠΆΠΈ.
ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°, Π½Π°Ρ ΠΎΠ΄ΡΡΠΈΠ΅ΡΡ Π² Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°ΡΠ΅, ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡ ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΡ (ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΡ) Π³Π΅ΠΏΠ°ΡΠΎΡΠΈΡΠΎΠ², ΠΏΡΠΎΡΠ²Π»ΡΡΡ Π΄Π΅Π·ΠΈΠ½ΡΠΎΠΊΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π°, ΡΠ½ΠΈΠΆΠ°ΡΡ ΠΎΡΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ Π»ΠΈΠΏΠΈΠ΄ΠΎΠ² ΠΈ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π° Π² ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΊΠ°Ρ , ΠΏΠΎΠ²ΡΡΠ°ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΊΠ°Π½Π΅Π²ΠΎΠ³ΠΎ Π΄ΡΡ Π°Π½ΠΈΡ, Π°ΠΊΡΠΈΠ²ΠΈΠ·ΠΈΡΡΡΡ ΠΎΠ±ΠΌΠ΅Π½ Π²Π΅ΡΠ΅ΡΡΠ² Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΡΠ½ΠΈΠΆΠ°ΡΡ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ.
ΠΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΠΊ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ»Π΅Π΄ΡΡΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ: Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΡΡΡΠΈΠΉ Π³Π΅ΡΠΏΠ΅Ρ, Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΈΡ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ (Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅, ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΡΠΉ). Π Π²ΠΈΠ΄Π΅ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ: ΡΡΠ΅Π°ΡΠΎΠ³Π΅ΠΏΠ°ΡΠΈΡΠ°Ρ (Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ, ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎΠΉ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ).
ΠΡΠΎΡΠΈΠ²ΠΎΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΠΠΈΠΏΠ΅ΡΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ, Π΄Π΅ΡΡΠΊΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ, Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΡ, ΠΏΠ΅ΡΠΈΠΎΠ΄ Π»Π°ΠΊΡΠ°ΡΠΈΠΈ.
Π‘ ΠΎΡΡΠΎΡΠΎΠΆΠ½ΠΎΡΡΡΡ Π‘ ΠΎΡΡΠΎΡΠΎΠΆΠ½ΠΎΡΡΡΡ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ ΠΏΠΎΠ»ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ Π°Π»Π»Π΅ΡΠ³ΠΈΠ΅ΠΉ Π½Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ, Π° ΡΠ°ΠΊΠΆΠ΅ Ρ Π»ΠΈΡ ΠΏΠΎΠΆΠΈΠ»ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°.
Π‘ΠΏΠΎΡΠΎΠ± ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΈ Π΄ΠΎΠ·Ρ
- ΠΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΡΡΡΠ΅ΠΌ Π³Π΅ΡΠΏΠ΅ΡΠ΅ ΠΈ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ΅: Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎΠ΅ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅: 10 ΠΌΠ» (560 ΠΌΠ³ Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°ΡΠ° ΠΏΠ»Π°ΡΠ΅Π½ΡΡ) ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° (5 Π°ΠΌΠΏΡΠ») ΡΠ°ΡΡΠ²ΠΎΡΡΡΡ Π² 250 -500 ΠΌΠ» 5% ΡΠ°ΡΡΠ²ΠΎΡΠ° Π΄Π΅ΠΊΡΡΡΠΎΠ·Ρ ΠΈΠ»ΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° ΠΈ Π²Π²ΠΎΠ΄ΡΡ ΡΠ΅ΡΠ΅Π· Π»ΠΎΠΊΡΠ΅Π²ΡΡ Π²Π΅Π½Ρ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 1,5 — 2 ΡΠ°ΡΠΎΠ². ΠΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡ 3 ΡΠ°Π·Π° Π² Π½Π΅Π΄Π΅Π»Ρ Ρ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠΌ Π² 2 Π΄Π½Ρ. ΠΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ 10 ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ.
- ΠΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ: ΡΡΠ΅Π°ΡΠΎΠ³Π΅ΠΏΠ°ΡΠΈΡΠ°Ρ (Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ, ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎΠΉ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ): Π²Π½ΡΡΡΠΈΠΌΡΡΠ΅ΡΠ½ΠΎ: ΠΏΠΎ 2 ΠΌΠ» Π² ΡΡΡΠΊΠΈ (112 ΠΌΠ³ Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°ΡΠ° ΠΏΠ»Π°ΡΠ΅Π½ΡΡ). Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠΆΠ΅ΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΠ° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½Π° Π΄ΠΎ 2 -3 ΡΠ°Π· (Π΄ΠΎ 6 ΠΌΠ») Π² ΡΡΡΠΊΠΈ; Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎΠ΅ ΠΊΠ°ΠΏΠ΅Π»ΡΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅: 10 ΠΌΠ» (560 ΠΌΠ³ Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ·Π°ΡΠ° ΠΏΠ»Π°ΡΠ΅Π½ΡΡ) ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° (5 Π°ΠΌΠΏΡΠ») ΡΠ°ΡΡΠ²ΠΎΡΡΡΡ Π² 250 -500 ΠΌΠ» 5% ΡΠ°ΡΡΠ²ΠΎΡΠ° Π΄Π΅ΠΊΡΡΡΠΎΠ·Ρ ΠΈΠ»ΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° ΠΈ Π²Π²ΠΎΠ΄ΡΡ ΡΠ΅ΡΠ΅Π· Π»ΠΎΠΊΡΠ΅Π²ΡΡ Π²Π΅Π½Ρ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 1,5 — 2 ΡΠ°ΡΠΎΠ². ΠΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡ Π΅ΠΆΠ΅Π΄Π½Π΅Π²Π½ΠΎ. ΠΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ 2- 3 Π½Π΅Π΄Π΅Π»ΠΈ.
ΠΠΎΠ±ΠΎΡΠ½ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Ρ 3,7% Π±ΠΎΠ»ΡΠ½ΡΡ .
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ.
ΠΠΎΠ·ΠΌΠΎΠΆΠ½Ρ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π°Π½Π°ΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠΎΠΊ.
ΠΡΡΠ³ΠΈΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π»Π΅Π½ΠΈΡ
ΠΠΎΠ»Π΅Π·Π½Π΅Π½Π½ΠΎΡΡΡ Π² ΠΌΠ΅ΡΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ | 2.56% |
ΠΠ»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΏΠΎΠΊΡΠ°ΡΠ½Π΅Π½ΠΈΠ΅, Π·ΡΠ΄ ΠΊΠΎΠΆΠΈ) | 0.37% |
ΠΠ½Π΅ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π² ΠΌΠ΅ΡΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ | 0.37% |
ΠΠΈΠ½Π΅ΠΊΠΎΠΌΠ°ΡΡΠΈΡ (ΠΏΡΠΈΡΠΈΠ½Π½ΠΎ-ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠ²ΡΠ·Ρ Ρ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π½Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π°) | 0.37% |
ΠΠ΅ΡΠ΅Π΄ΠΎΠ·ΠΈΡΠΎΠ²ΠΊΠ°: Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΎ ΡΠ»ΡΡΠ°ΡΡ ΠΏΠ΅ΡΠ΅Π΄ΠΎΠ·ΠΈΡΠΎΠ²ΠΊΠΈ ΠΠ°Π΅Π½Π½Π΅ΠΊΠ° Π½Π΅ ΡΠΎΠΎΠ±ΡΠ°Π»ΠΎΡΡ.
ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π°ΠΌΠΈ ΠΡΠΈ ΡΠΌΠ΅ΡΠΈΠ²Π°Π½ΠΈΠΈ ΠΠ°Π΅Π½Π½Π΅ΠΊΠ° Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, ΡΠ²Π»ΡΡΡΠΈΠΌΠΈΡΡ ΡΠΈΠ»ΡΠ½ΡΠΌΠΈ ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ (ΡΠ Π²ΡΡΠ΅ 8.5), Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Π΅Π³ΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ½ΠΈΠΆΠ°Π΅ΡΡΡ. Π‘Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ ΠΊΠ°ΠΊΠΈΡ -Π»ΠΈΠ±ΠΎ Π΄ΡΡΠ³ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡΡ ΠΠ°Π΅Π½Π½Π΅ΠΊΠ° Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΎΡΡΡΡΡΡΠ²ΡΡΡ.
ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΈ Π³ΡΡΠ΄Π½ΠΎΠ³ΠΎ Π²ΡΠΊΠ°ΡΠΌΠ»ΠΈΠ²Π°Π½ΠΈΡ ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΈ Π³ΡΡΠ΄Π½ΠΎΠ³ΠΎ Π²ΡΠΊΠ°ΡΠΌΠ»ΠΈΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ.
ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠ°Π΅Π½Π½Π΅ΠΊΠ° Ρ Π½Π΅Π΄ΠΎΠ½ΠΎΡΠ΅Π½Π½ΡΡ Π΄Π΅ΡΠ΅ΠΉ, Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΡΡ Π³ΡΡΠ΄Π½ΡΡ ΠΈ Π½Π΅ΡΠΎΠ²Π΅ΡΡΠ΅Π½Π½ΠΎΠ»Π΅ΡΠ½ΠΈΡ Π΄Π΅ΡΠ΅ΠΉ Π½Π΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Ρ Π΄Π΅ΡΠ΅ΠΉ Π½Π΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ΅ΡΡΡ.
ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Ρ ΠΏΠΎΠΆΠΈΠ»ΡΡ Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΈΠΌΠ΅ΡΡΠΈΠΌΡΡ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π΄Π°Π½Π½ΡΠΌ ΠΏΠΎΠΆΠΈΠ»ΠΎΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ Π½Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠ΅ΠΌ Π΄Π»Ρ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠ°Π΅Π½Π½Π΅ΠΊΠ°. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅, ΠΏΠΎΡΠΊΠΎΠ»ΡΠΊΡ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ Ρ ΠΏΠΎΠΆΠΈΠ»ΡΡ Π»ΡΠ΄Π΅ΠΉ ΡΡ ΡΠ΄ΡΠ°ΡΡΡΡ, ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π΄ΠΎΠ»ΠΆΠ½ΠΎ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡΡΡ ΠΏΠΎΠ΄ ΡΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ.
Π‘Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΌ Π²Π»ΠΈΡΠ½ΠΈΠΈ Π½Π° ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΡΠΏΡΠ°Π²Π»ΡΡΡ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ½ΡΠΌΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π°ΠΌΠΈ, ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ ΠΠ»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΡΠΏΡΠ°Π²Π»ΡΡΡ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ½ΡΠΌΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π°ΠΌΠΈ, ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ Π½Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ.
Π€ΠΎΡΠΌΠ° Π²ΡΠΏΡΡΠΊΠ° Π Π°ΡΡΠ²ΠΎΡ Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ. ΠΠΎ 2 ΠΌΠ» Π² Π°ΠΌΠΏΡΠ»Π°Ρ ΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΡΡΠ΅ΠΊΠ»Π° Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° 2. ΠΠ°ΠΆΠ΄Π°Ρ Π°ΠΌΠΏΡΠ»Π° ΠΈΠΌΠ΅Π΅Ρ ΠΏΡΡΠ½ΠΎ Π±Π΅Π»ΠΎΠ³ΠΎ ΡΠ²Π΅ΡΠ°, ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ°ΡΡΠ΅Π΅ ΠΌΠ΅ΡΡΠΎ Π½Π°Π΄Π»ΠΎΠΌΠ° Π°ΠΌΠΏΡΠ»Ρ. ΠΠΎ 10 ΠΈΠ»ΠΈ 50 Π°ΠΌΠΏΡΠ» Π² ΠΊΠ°ΡΡΠΎΠ½Π½ΡΡ ΠΏΠ°ΡΠΊΡ Ρ ΠΏΠ΅ΡΠ΅Π³ΠΎΡΠΎΠ΄ΠΊΠ°ΠΌΠΈ ΠΈΠ· ΠΊΠ°ΡΡΠΎΠ½Π° Ρ ΠΈΠ½ΡΡΡΡΠΊΡΠΈΠ΅ΠΉ ΠΏΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ.
Π‘ΡΠΎΠΊ Π³ΠΎΠ΄Π½ΠΎΡΡΠΈ 3 Π³ΠΎΠ΄Π°. ΠΠ΅ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ ΠΏΠΎ ΠΈΡΡΠ΅ΡΠ΅Π½ΠΈΠΈ ΡΡΠΎΠΊΠ° Π³ΠΎΠ΄Π½ΠΎΡΡΠΈ, ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠ³ΠΎ Π½Π° ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠ΅.
Π£ΡΠ»ΠΎΠ²ΠΈΡ Ρ
ΡΠ°Π½Π΅Π½ΠΈΡ
ΠΡΠΈ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠ΅ ΠΎΡ +18 Π΄ΠΎ +25Β° Π‘ Π² Π·Π°ΡΠΈΡΠ΅Π½Π½ΠΎΠΌ ΠΎΡ ΡΠ²Π΅ΡΠ° ΠΌΠ΅ΡΡΠ΅.
Π₯ΡΠ°Π½ΠΈΡΡ Π² ΠΌΠ΅ΡΡΠ°Ρ
, Π½Π΅Π΄ΠΎΡΡΡΠΏΠ½ΡΡ
Π΄Π»Ρ Π΄Π΅ΡΠ΅ΠΉ.
Π£ΡΠ»ΠΎΠ²ΠΈΡ ΠΎΡΠΏΡΡΠΊΠ° ΠΈΠ· Π°ΠΏΡΠ΅ΠΊ ΠΠΎ ΡΠ΅ΡΠ΅ΠΏΡΡ.
ΠΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ ΠΠΆΠ°ΠΏΠ°Π½ ΠΠΈΠΎ ΠΡΠΎΠ΄Π°ΠΊΡΡ ΠΠΎ., ΠΡΠ΄, 1-44-4, Π’ΠΎΠΌΠΈΠ³Π°Ρ Π¨ΠΈΠ±ΡΡ-ΠΊΡ, Π’ΠΎΠΊΠΈΠΎ, 151-0063, Π―ΠΏΠΎΠ½ΠΈΡ.
ΠΠ»Π°Π΄Π΅Π»Π΅Ρ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ΄ΠΎΡΡΠΎΠ²Π΅ΡΠ΅Π½ΠΈΡ/ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ, ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΠ°Ρ ΠΏΡΠ΅ΡΠ΅Π½Π·ΠΈΠΈ/ ΠΠΊΡΠΊΠ»ΡΠ·ΠΈΠ²Π½ΡΠΉ Π΄ΠΈΡΡΡΠΈΠ±ΡΡΡΠΎΡ Π² Π ΠΎΡΡΠΈΠΈ ΠΠΠ ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ ΠΠΎΡΠΏΠΎΡΠ°ΡΠΈΡ Β«Π ΠΠΠΒ», Π ΠΎΡΡΠΈΡ, 123242, Π³. ΠΠΎΡΠΊΠ²Π°, ΡΠ». ΠΠΎΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ, Π΄.22, ΡΠ΅Π».: +7(499) 766-27-27
90000 Buy Laennec 2 ml X 50 vials for anti-aging and skin tightening with placenta hydrolysate online from Japan 90001 90002 Basic information about Laennec 90003 90004 90005 Official manufacturer 90006: JBP Co Ltd, Japan 90007 90004 90005 Active ingredient: 90006 human placenta hydrolysate. 90007 90004 90005 Selling start 90006: July, 1979, in Japan after clinical trials (conducted throughout the Japan in 124 cases).90007 90004 90005 Official Code 90006 in Japan: 3259601A1024 90007 90004 Laennec is officially registered in USA, South Korea, China, Russia and NIS countries. 90007 90004 90023 90005 Clinically significant adverse reactions and Contraindications 90006 90026: allergic reactions are possible. 90007 90004 90005 FREE WORLDWIDE SHIPPING! WE SHIP TO YOUR COUNTRY! 90006 90007 90004 90005 BEST OFFER 789 USD FOR BANK PAYMENT ONLY — CONTACT US NOW! 90006 90007 90002 Related Articles about Laennec 90003 90004 Where can I get detailed information about clinical studies of laennec? Is Laennec a really effective medicine? What differs Laennec from similar Japanese placenta injections? If you’d like to know answers for these questions, our articles below may help you.90007 90002 Clinical studies of Laennec 90003 90004 Clinical trials were conducted throughout Japan. As a result, positive effects on blood counts such as GOT and GPT were recognized. Furthermore, Laennec was used in a number of liver and lung diseases. Similarly, it showed high regeneration and recovery effects. Studies were conducted at 95% intervals, for a more accurate effect. In addition, doctors conducted placebo tests to achieve even more accurate results. Side effects identified during the tests include allergies in 3.7% of patients. In less than one percent, itching and numbness were observed. But a clear connection between the injection and these symptoms has not been scientifically established. It is highly not recommended to use the medicine during pregnancy and breastfeeding. 90007 90004 Laennec appears in a variety of publications and scientific studies of medical subjects in Japan. For instance, the medical effect of Laennec in the treatment of the liver was investigated by the doctor Ueda Hideo.His research Acta hepatologica Japonica Vol.15 (δΈ η°θ±ι θ θ, vol.15 162 ΡΠΈΡΡΡΠ° Π΄Π΅Π²’ΡΡΡΠΎΡ ΡΡΠΌΠ΄Π΅ΡΡΡ ΡΠΎΡΠΈΡΠΈ (click here to follow) shows the positive effects of applying Laennec during clinical trials. Besides that, Dr. Sakamoto Koji (ε ζ¬ ζ΅© δΊ) performed researches on anti -age therapy and treatment of diseases of internal organs using cell regeneration in the University of Tokyo Medical Journal (ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ). Dr. Sakamoto paid special and deep attention to detailed clinical research on side effects before launching Laennec in Japan — in the issue of ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ, vol.33,271 (1975) as well as ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ, vol.31,829 (1973) and in ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ, vol.32,351 (1974).90007 90002 Dosage and administration for Laennec 90003 90004 In chronic recurrent herpes and atopic dermatitis, Laennec is injected via IV. 10 ml (560 mg of placental hydrolyzate) of the medicine (5 vials) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5 -2 h. Injections are carried out 3 times a week with an interval of 2 days. Over all, the course of treatment includes 10 injections. 90007 90004 90007 90004 In chronic liver diseases (steatohepatitis, alcoholic, metabolic, and mixed etiology), the drug is administered intramuscularly at 2 ml / day (112 mg of placental hydrolyzate).Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (6 ml) / day. Also the medicine can be injected via IV. 10 ml (560 mg of placentae hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5-2 hours. Injections are carried out daily. In that case, the course of treatment is 2-3 weeks. 90007 90004 90007 90056 BEWARE OF FALSE LAENNEC FROM KOREA AND CHINA! 90057 90004 It is very important to identify original Laennec from Chinese and Korean fake copies.Original Laennec is shipped only from Japan (from hospital). And it is never sold on domestic market, because that’s a violation of Japan Law. 90007 90004 90005 Expiration date is 1 year. Laennec manufactured in Japan differs from placenta hydrolysate manufactured in other countries. It contains tried-and-true components, it has better effec. But its shelf life is 1 year only. 90006 90007 90004 PLEASE PAY ATTENTION! 90007 90004 Expiry date is less than 1 year (about 7-9 months).One box of 50 vials is for 5-6 months course. Apply one vial every 2 days for 2 months, then repeat in 1 — 1,5 months. — 90007 90004 Product is shipped directly from Japan only. 90005 WE SHIP IN 5-7 BUSINESS DAYS. 90006 90007 90002 Laennec from Japan: Dummy or Effective medicine? 90003 90004 Certainly, clients often write us different questions about Laennec. How to get original Japanese Laennec? How to distinguish a fake and original product? And, especially recently, many people asked us whether Laennec will be effective in case of this or that disease.Some people believe it might be effective in treating cancer, oncology, stroke, kidney failure, diabetes and so on. We feel very much concerned about it because those misbeliefs might be dangerous. Where do you, dear customers, take these data (about the potential effectiveness of the Laennec in case of oncology, etc.)? We will do our best to clarify the situation once and for all. 90007 90002 What Laennec is effective for? 90003 90004 Please, remember, the Japanese Laennec is effective for the following deseases and conditions.First, liver diseases, including hepatitis. But severe cases requirs additional treatment and other medicines. Second, for skin diseases, including psoriasis, except for severe cases). Third, for the purpose of rejuvenating and antiaging therapy. The last purpose is not certified by medical supervisory authorities in number of countries. However, it has been fully proved and confirmed in Japan and the USA. The efficacy of placental preparations has been also proven in Korea, where some of JBP products are produced.90007 90002 How to identify genuine Laennec from Japan? 90003 90004 Japanese-made Laennec can be purchased only in Japan. You can not purchase it neither in China, nor in the Philippines or in Thailand! Unfortunately, fakes exist even in Japan. For instance, they are sold from companies without a license or through net auctions like Ebay. On this product page, there is a complete guide on how to distinguish the original Japanese Laennec. Customers sent us photos of goods purchased in other countries.Ampoules have different lengths, shape, heterogeneous colour etc. Prints on the packaging are dirty, leaving stains and marks. But even this is not the main point though a sufficient one. There is a simple and reliable way to distinguish a true Laennec from Japan. 90007 90056 How to identify genuine Laennec from Japan? 90057 90004 Pay attention to the packaging and the ampoules. On the packaging there is a unique three-dimensional volumetric code, which is hard enough to make and almost impossible to copy.Furthermore, on each ampoule of the Laennec there are two long numeric codes. These two codes are special labeling as required by the Japanese Medicines Act dated year 2008. The upper code is the sales lot code. And the lower code is the code of the batch of pharmaceutical raw materials used for production. In other words, one code is responsible for the sale, the second for the manufacture. 90007 90056 How to apply Laennec in right way? 90057 90004 Applying the medicine should be carried out strictly under the supervision of a specialist or doctor.Base dosages can be found on this page. The product can be used intramuscularly, intravenously and for mesotherapy. Pay attention, if there are allergic reactions or any uncomfortable sensations, the application of the Laennec should be stopped immediately. HUMAN PLACENTA. ANTI-AGING, WHITENING, MOISTURIZING 100% human Placenta Laennec. Original, directly from Japan. From Maker and official distributor. 2 ml * 50 pcs. 90007 90056 CLICK HERE AND ASK ANY QUESTION! GET ANSWER IN 24 HOURS 90057 90056 CLICK TO CHECK OUR GUARANTEES & CUSTOMER REVIEWS 90057 90004 90005 WORLDWIDE SHIPPING.FIXED RATE AS LOW AS $ 19 PER PARCEL 90006 90007 90002 How to identify original product? 90003 90004 90103 1. Original JBP package for domestic market. 90104 90007 90004 90107 90007 90004 2. Made in Japan marking on the side of original package. ( «Manufactured and Distributed by JBP Japan»). 90007 90004 90112 90007 90004 3. Expiry date and bar code. At the bottom there is a serial number of product. Specific 3D bar code with series and number (on the picture old code is shown, we always ship goods with 8-9 months ‘expiry date that is enought for full course.Box has pharma serial number and sales lot serial nuber (japanese control system). We covered series for privacy reasons. 90007 90004 90117 90007 90004 4. Ampoules of correct shape with serial number and bar code on every vial. 90007 90004 90122 90007 90004 90005 To protect privacy of our distributor we have hidden bar codes and serial number! 90006 90007 90004 5. For all laennec with expiration date of 2019.07 and further there is additional sticker added to package for protection reasons, as showm below.90007 90004 90131 90007 90002 Laennec is effective for: 90003 90004 90005 Common ailments 90006 90007 90139 90140 General fatigue 90141 90140 Stiffness of shoulders 90141 90140 Anemia 90141 90140 Raynaud disease 90141 90148 90004 90005 Male and female sexual sphere 90006 90007 90139 90140 Prostatic hypertrophy 90141 90140 Menopause and Andropause (male menopause) 90141 90140 Dysmenorrhea 90141 90140 Ovarian Dysfunction 90141 90140 Frigidity 90141 90148 90004 90005 Alimentary system 90006 90007 90139 90140 Chronic constipation 90141 90140 Gastroptosis 90141 90140 Gastric ulcer 90141 90140 Dyspepsia 90141 90140 Hepatitis 90141 90140 Liver cirrhosis 90141 90148 90004 90005 Skin 90006 90007 90139 90140 Urticaria (hives) 90141 90140 Eczema 90141 90140 Melasma 90141 90140 Keloid scar 90141 90140 Lupus 90141 90148 90002 100% HUMAN PLACENTA EXTRACT 90003 90004 100% Human Placenta Extract (HPE) is proven to be beneficial to human body.Japanese government acknowledged it as an alternative medicine for anti-aging program. Also, the American National Agency for Food and Drug did agree with that. Naturally, HPE is more compatible and harmless for humans rather than Animal Placenta Extract. Certified in Japan, USA and Korea, this is currently one of the most effective and reliable injectable medicines. 90007 90056 90005 Official Japanese Certificate 90006 90057 90004 90208 90007 90004 Delivery time — 10-15 days after the order.Order is processed at beauty clinic, Niigata prefecture. 90007 90004 90005 PRICE 789 USD FOR BANK PAYMENTS ONLY — CONTACT US NOW! 90006 90007 90004 90005 ORDER 3 BOXES BY BANK, GET 450 USD (739 USD PER BOX) DICSOUNT NOW! 90006 90007 90004 90005 You can order 10 vials here (click) 90006 90007 90004 E-mail us your name and address, we shall issue an invoice. You will purchase Original Laennec from Japan for 789 usd! When purchased online, the price is 889 usd.90007 90004 90005 FREE WORLDWIDE DELIVERY! WE SHIP TO YOUR COUNTRY! 90006 90007 .90000 Japan Bio Products Co., Ltd. 90001 90002 Laennec is the ethical drug manufactured with JBP’s unique technologies. 90003 90004 Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver.Our product safety is ensured by the most rigid safety measures among existing scientific standards. 90005 90004 90007 Warning: 90008 90007 As LAENNEC Injection is an ethical drug, JBP has never sold it on Internet. 90008 90005 90012 90013 90014 90015 90016 90015 Ingredients 90016 90015 Content 90016 90015 Remarks 90016 90023 90014 90015 Active ingredient 90016 90015 Water-soluble substance of a product of enzymatic human placenta 90016 90015 112 mg 90016 90015 Ingredient extracted from human placenta 90016 90023 90014 90035 Inactive ingredients 90016 90015 Pepsin 90016 90015 Trace 90016 90015 Gastric mucosal extract 90016 90023 90014 90015 Lactose 90016 90015 0.6 mg 90016 90015 — 90016 90023 90014 90015 pH adjuster 90016 90015 q.s. 90016 90015 — 90016 90023 90060 90061 90004 90007 Description 90064 90008 This product is a light yellow-brown or yellow-brown clear liquid with a distinctive odor. The pH level ranges from 5.5 to 6.5 and the osmotic pressure ratio (to physiological saline) is approximately one. 90005 90004 90007 Indications 90064 90008 Improvement of hepatic function in chronic hepatic disease.90005 90004 90007 Dosage and administration 90064 90008 The normal adult dose is a 2 ml subcutaneous or intramuscular injection once daily. According to symptoms, the dose can be increased to 2 or 3 times daily. 90005 90004 90007 Packaging 90064 90008 2 ml 50 ampoules 90005 90002 Cautions for use ** 90007 90008 90003 90004 90007 1. Careful Administration 90064 90008 LAENNEC should be administrated with care in patients predisposed to allergies. 90005 90004 90007 2. Important Basic Cautions 90064 90008 This product is manufactured from the extract of human placenta delivered full-term in Japan.In order to screen each donor, a complete medical history, interviewing such as a history of travel and serologic testing for viruses, bacteria and infection are performed, after nucleic-acid testing (NAT) to meet with requirements for HBV-DNA, HCV- RNA and HIV-1-RNA is carried out. In addition, it has been confirmed that high-pressure steam sterilization for 20 minutes at 121 Β° C during the manufacturing process is effective in inactivating various viruses such as HIV etc. Furthermore, although in the product test, the nucleic-acid test meets with requirements for HBV-DNA, HCV-RNA, HIV-1-RNA, HTLV-DNA, and parvovirus B19-DNA, patients should be made aware of the following points during administration: To date, the transmission of infection, such as variant Creutzfeldt-Jakob disease (vCJD), by administration of this product in Japan or other countries has not been reported.However, although safety measures are taken to prevent infection during the manufacturing process, it is theoretically impossible to fully eliminate the risks of infection transmission originating in a human placenta used as raw material. While safety measures during the manufacturing process to prevent infection, as well as confirmation of the necessity of treatment for the disease before administration are carried out, doctors should explain to patients and try to have them understand that when human placenta is used as the raw material of a product, the risk of infection can not be fully ruled out.90005 90004 90007 3. Drug Interactions 90064 90008 When this product is directly mixed with a strong base preparation of pH 8.5 or more, attenuation of pharmacological activity has been reported. 90064 No coadministration with this product resulting in the enhancement or attenuation of the pharmacological effect of this product or concomitant drugs, appearance of adverse reactions, or aggravation of disease has been reported. 90005 90004 Adverse reactions or patients who were suspected to have suffered adverse reactions to this product were reported in a total of 10 (3.7%) of the 273 patients selected for safety evaluation in the clinical study performed during implementation of reevaluation of the drug efficacy. The most frequently observed adverse reactions were injection site pain in 7 patients (2.6%), hypersensitivity (such as rash, fever, and itching) in 1 patient (0.4%), injection site indurations in 1 patient (0.4%), and gynaecomastia in 1 patient (0.4%). The causal relationship between gynaecomastia and this product is unknown. 90064 No abnormal changes in laboratory values ββwere observed.90104 1) 90064 90106 β’ Clinically significant adverse reactions 90064 ** Shock (incidence unknown): 90064 Since this product is a protein / amino acid preparation derived from human tissue, this product may cause a shock. If any signs of abnormality are observed, the drug should be discontinued immediately, appropriate measures should be taken and the condition should be monitored fully. 90064 β’ Other adverse reactions (in descending order of occurrence) 90005 90111 90013 90014 90015 Injection site pain 90016 90015 2.56% 90016 90023 90014 90015 Sensitivity (rash, fever, itching etc.) 90016 90015 0.37% 90016 90023 90014 90015 Injection site indurations 90016 90015 0.37% 90016 90023 90014 90015 Gynaecomastia 90016 90015 0.37% 90016 90023 90060 90061 90004 90007 4. Use in the Elderly 90064 90008 From clinical data and present use, no particular caution is needed in the administration of this product to the elderly.However, since elderly patients often have reduced physiological function, it should be administrated with care. 90005 90004 90007 5. Use during Pregnancy. Delivery or Lactation 90064 90008 In reproductive development toxicity experiments on animals, including teratogenicity, this product can be considered not to have such toxicity. 90104 2) 90106 90005 90004 90007 6. Pediatric use 90064 90008 The safety of this product in premature infants, newborns, infants, toddlers or children has not been established due to insufficient clinical data.90005 90004 90007 7. Overdosage 90064 90008 Overdosage of this product and the resulting efficacy or safety have not been established (Due to insufficient clinical data). 90005 90004 90007 8. Precautions for Use 90064 90008 Injection site: 90064 In order to avoid any effect on tissue or nerves, the product should be injected subcutaneously or intramuscularly taking the following precautions: 90064 a) For the injection site, to avoid nerve pathways, it should be administrated with care.90064 b) In the case of repeated injections, avoid injecting into the same site by alternating on the left and right side etc. 90064 c) If intense pain or regurgitation of blood is observed, the needle should be removed immediately, and injected into a different site. 90064 Opening the ampoule: 90064 When opening the ampoule, it is preferable to wipe the part to be cut with an ethanol sponge before opening it. 90005 90004 90005 90002 Pharmacokinetics 90003 90004 The bioactive ingredients of LAENNEC are extracted from human placenta, and the primary pharmacological effects of this product can not necessarily be attributed to a single substance or ingredient.Therefore, evaluation of the pharmacokinetics (absorption, distribution, metabolism, and excretion) of this product has not been established. 90005 90004 90005 90002 Clinical studies 90003 90004 90007 1. Double blind comparison to chronic hepatitis and hepatic cirrhosis 90104 1) 90064 90106 90008 In a double-blind crossover study of 124 patients in Japan on the effects of this product on chronic hepatitis and hepatic cirrhosis, administration of this product improved serum transaminase (GOT, GPT) levels significantly (see figures below).90005 90004 Efficacy to GOT 90064 90005 90004 Efficacy to GPT 90064 90005 90004 Summary of drug-efficacy 90064 [(A) Items having a tendence to decrease or increase significantly by Laennec] 90005 90004 Data on pharmacological reevaluation 90064 Summary of drug-efficacy 90064 [(B) Items having a tendence to decrease or increase significantly by Placebo] 90005 90004 90007 2. Action on HCV-RNA levels 90104 3) 90064 90106 90008 Twenty subjects of two-agent combination therapy only with Stronger Neo-Minophagen C and Acelart were performed in the past and negativation neither of C100-3 antibody nor HCV-RNA was admitted in them.In three-agent combination therapy with Laennec added, two negative cases of serum HCV-RNA levels were admitted. 90005 90004 90005 90002 Pharmacology 90003 90004 90007 1. Stimulatory effects of hepatic reproduction 90104 4), 5) 90064 90106 90008 After 70% of livers in healthy rats was resected, time comparisons of liver weight to the control groups resulted in significant stimulation of hepatic reproduction in the Laennec groups. 90005 90004 90007 2. Stimulatory effects of cellular DNA synthesis 90104 4) 90064 90106 90008 Compared to control groups, in vivo experimental system using primary culture rat hepatocytes, the DNA-synthesis accelerator activity was observed in 2 ΞΌL / ml-administrated groups.That accelerator activity was equivalent to 10 pM of rHGF. The liver tissue in vivo experimental system using rats with acute hepatitis by ANIT was stained and the result of evaluation of the rate of hepatocyte nucleus in DNA synthesis period showed significant accelerator of DNA synthesis compared to the control groups. 90005 90004 90007 3. Inhibitory effects of experimental liver injury 90104 4), 6) 90064 90106 90008 Compared to control groups, in vivo experimental system using rats with acute hepatitis by ANIT, the liver cytosolic enzymes in serum (GPT, ALP, LAP and g -GTP) and the bilirubin levels significantly degreased in the Laennec groups.90064 In addition, compared to control groups, in vivo experimental system using rats with acute hepatitis and chronic hepatitis by CCI4, the liver cytosolic enzymes in serum (GPT, GOT) significantly degreased and histopathologically improved liver disorder in the Laennec groups. 90005 90004 90007 4. Anti-fatty liver action 90104 7) 90064 90106 90008 A 5-day subcutaneous injection of 1.2 ml / kg of this product in rats suffering from acute hepatic disorder with CCI4 resulted in a significant decrease in hepatic weight to body weight as compared with the control groups.Furthermore, total hepatic lipids and total hepatic cholesterol decreased significantly in the 3.6 ml / kg dose groups, and hepatohistological findings to support such results were seen and the body weight was realized. 90064 After pretreatment of acute hepatic disorder with CCI4, there were no significant differences with regards to biochemical findings between the control groups and when 5-day repeated, subcutaneous administration of 1.2 ml / kg of this product was performed. However, in the 3.6-ml / kg dose groups, maintenance of lobular structure was better than the control groups with regards to hepatohistological findings.90005 90004 90007 5. Absorption accelerated activity on interstitial connective tissue 90104 8) 90064 90106 90008 This product exhibited inhibitory action of fibroplasias in rat liver due to 12-week repeated administration of CCI4, and it was confirmed histologically that once multiplied, interstitial connective tissues were absorbed. 90005 90004 90005 90002 Physicochemistry 90003 90004 This product is human-placental extract, and contains various biological active substances. However, the active ingredients of this agent can not be specified as a single substance or several sorts of substances.90005 90004 90005 90002 Precautions for handling * 90003 90004 This product corresponds to a specialized biological product. Therefore, when this product is administrated, the product name, manufacturing No., date of administration (or prescription), name and address of patients should be reported and stored for at least 20 years in accordance with the order issued by the Japanese Ministry of Health, Labour and Welfare. This product should be used with attention to the point that the indication of this product is «improvement of hepatic function in chronic liver disease».90005 90004 90005 90004 90007 References 90064 90008 1) Ueda H. et al .: Kanzo (Liver), vol.15, 162, 1974 90064 2) Taniguchi H. et al .: data on file in Japan Bio Products Co. Ltd., 1985-1991 90064 3) Takami T .: Kiso to Rinsho, vol.30, 3549, 1996. 90064 4) Liu K. et al .: Yakuri to Rinsho, vol.5, 2187, 1995 90064 5) Sakamoto K . et al .: Journal of Tokyo Medical University, vol.33, 271, 1975 90064 6) Nakayama S. et al .: Folia Pharmacologica Japonica, vol.94, 289, 1989 90064 7) Sakamoto K. et al.: Journal of Tokyo Medical University, vol.31, 829, 1973 90005 .90000 Buy Laennec essence 2 ml * 50 vials for Anti-aging online at sale price 90001 90002 90003 FREE WORLDWIDE SHIPPING! WE SHIP TO YOUR COUNTRY! 90004 90005 90002 90003 BEST PRICE 789 USD FOR BANK PAYMENT ONLY — CONTACT US NOW! PAY BY BANK 90004 90005 90002 90003 ORDER 3 BOXES, GET 450 USD (739 USD PER BOX) DICSOUNT NOW! 90004 90005 90002 90003 You can also check 10 vials here (click) 90004 90005 90018 Basic information on Laennec injections.90019 90002 90003 Official manufacturer 90004: JBP Co Ltd, Japan 90005 90002 90003 Active ingredient: 90004 human placenta hydrolysate. 90005 90002 90003 Start sales 90004: in Japan after clinical trials (conducted throughout the Japan in 124 cases) of Laennec in 1979, July. 90005 90002 90003 Official Code 90004 in Japan: 3259601A1024 90005 90002 Laennec is registered in USA, South Korea, China, Russia and NIS countries officially. 90005 90002 Clinically significant adverse reactions and 90003 Contraindications 90004: allergic reactions are possible 90005 90018 Clinical studies of Laennec: regarding medical effects.90019 90002 As a result of clinical trials conducted throughout Japan, positive effects on blood counts such as GOT and GPT were recognized — laennec was used in a number of liver and lung diseases, showing high regeneration and recovery effects. Studies were conducted at 95% intervals, for a more accurate effect, placebo tests was applied to achieve more accurate results. Side effects identified during the tests include allergies in 3.7% of patients. In less than one percent, itching and numbness were observed, but a clear connection between the injection and these symptoms has not been scientifically established.It is highly not recommended to use the drug during lactation and pregnancy. 90005 90002 Laennec appears in a variety of publications and scientific studies of medical subjects in Japan. The medical effect of Laenneca in the treatment of the liver was investigated by the doctor Ueda Hideo in his research Acta hepatologica Japonica Vol.15 (δΈ η°θ±ι θ θ, vol.15 162 1974 (click here to follow) the positive effects of applying Laennec during clinical trials are shown. Dr. Sakamoto Koji (ε ζ¬ ζ΅© δΊ) in his research on anti-age therapy and treatment of diseases of internal organs using cell regeneration in the University of Tokyo Medical Journal (ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ) pays special and deep attention to detailed clinical research on side effects before launching Laennec drug in Japan — in the issue of ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ, vol.33,271 (1975) as well as ζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ, vol.31,829 (1973) and inζ±δΊ¬ ε»η§ε€§ε¦ ι θͺ, vol.32,351 (1974).90005 90018 Dosage and administration of Laennec 90019 90002 Dosage: In chronic recurrent herpes and atopic dermatitis, the drug is injected via IV: 10 ml (560 mg of placental hydrolyzate) of the medicine (5 vials) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5 -2 h. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment 10 injections. 90005 90002 90005 90002 In chronic liver diseases (steatohepatitis / alcoholic, metabolic, and mixed etiology /), the drug is administered intramuscularly at 2 ml / day (112 mg of placental hydrolyzate).Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (6 ml) / day. The drug can be injected via IV: 10 ml (560 mg of placentae hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5-2 hours. Injections are carried out daily. The course of treatment is 2-3 weeks. 90005 90018 How to identify genuine Japanese Laennec? 90019 90002 BEWARE OF KOREAN AND CHINESE FAKE PRODUCTS! It is very important to identify original product from Chinese and Korean fake copies.Orignal product is shipped only from Japan (from hospital), and never sold on domestic market, as it is a violation of Japan Law. 90005 90002 PLEASE PAY ATTENTION! 90005 90062 90063 Expiration date is less then 1 year (about 9-10 monhs). One box of 50 vials is for 5-6 month course. Apply one vial every 2 days for 2 months, then repeat in 1 — 1,5 months. 90064 90063 Product is shipped directly from Japan. 90064 90063 ORIGINAL JAPANESE PACKAGE.MADE IN JAPAN — KURUME PLANT. 90064 90063 90003 Expiration date is 1 year. Laennec manufactured in Japan differs from Korean laennec, it contains natural components, has better effect but it’s shelf life is 1 year. 90004 90064 90063 WE SHIP IN about 5-7 business days after the order. 90064 90063 We ship 50 vials and 10 vials in original package. 90064 90077 90078 Laennec from Japan: Dummy or Effective medicine? 90079 90002 More and more often, clients write us different questions about Laennec.How to buy a original Japanese Laennec, how to distinguish a fake and original product and, especially recently, whether Laennec will be effective in case of his or that disease. Customers keep asking if it be effective in treating cancer, oncology, stroke, kidney failure, diabetes and so on. A list of questions about the efficacy of Laennec from Japan in this or that disease can be continued on and on. Where do you, dear customers, take these data (about the potential effectiveness of the Laennec in case of oncology, etc.) ?. We will do our best to clarify the situation once and for all. 90005 90078 What Laennec is effective for? 90079 90002 Please, remember, the Japanese Laennec is effective for liver diseases, including hepatitis (but severe case requires additional treatment and other drugs), for skin diseases (including psoriasis, except for severe cases), as well as for the purpose of rejuvenating and antiaging therapy. The last item is not certified by medical supervisory authorities in number of countries, but it has been fully proved and confirmed in Japan and the USA.The efficacy of placental preparations has been also proven in Korea, where some of JBP products are produced. In Japan laennec is also applied for skin tightening and general cellular anti-aging therapy. 90005 90078 How to buy genuine Laennec from Japan? 90079 90002 Japanese-made Laennec can be purchased only in Japan. Neither in China, nor in the Philippines or in Thailand, you can not buy it! And even in Japan there are fakes, when they are sold from companies without a license or on net auctions like Ebay.On this product page, there is a complete guide on how to distinguish the original drug and buy real, Japanese, Japanese-manufactured goods. Customers sent us photos of goods purchased in other countries — ampoules have different lengths, shape, heterogeneous colour etc. Prints on the packaging are dirty, leaving stains and marks. But even this is not the main thing though a sufficient one. There is a simple and reliable way to distinguish a true Laennec from Japan. 90005 90078 How to identify genuine Laennec from Japan? 90079 90002 Pay attention to the packaging and the ampoules.On the packaging there is a unique three-dimensional volumetric code, which is hard enough to make and almost impossible to copy. Furthermore, on each ampoule of the Laennec there are two long numeric codes. These two codes are special labeling as required by the Japanese Medicines Act dated year 2008. The upper code is the sales lot code, the lower code is the code of the batch of pharmaceutical raw materials used for production. That is, everything is simple enough — one code is responsible for the sale, the second for the manufacture.90005 90078 How to apply Laennec in right way? 90079 90002 Applying the drug should be carried out strictly under the supervision of a specialist or doctor. Base dosages can be found on this page. The drug can be used intramuscularly, intravenously and for mesotherapy. Pay attention, if there are allergic reactions or strange / uncomfortable sensations, the application of the Laennec should be stopped immediately. 90005 90018 Articles about Laennec 90019 90002 You may be interested to check the following articles related to laennec from our blog section: 90005 90002 90005 90002 90005 90002 HOW TO IDENTIFY ORIGINAL PRODUCT? 90005 90002 90109 1.Original JBP package for domestic market. 90110 90005 90002 90005 90002 90115 90005 90002 2. Made in Japan marking on the side of original package. ( «Manufactured and Distributed by JBP Japan»). 90005 90002 90120 90005 90002 3. Expiry date and bar code. At the bottom there is a serial number of product. Specific 3D bar code with series and number (on the picture old code is shown, we always ship goods with 8-9 months ‘expiry date that is enought for full course.Box has pharma serial number and sales lot serial nuber (japanese control system). We covered series for privacy reasons. 90005 90002 90125 90005 90002 4. Ampoules of correct shape with serial number and bar code on every vial. 90005 90002 90130 90005 90002 90003 To protect privacy of our distributor we have hidden bar codes and serial number! 90004 90005 90002 5. For all laennec with expiration date of 2019.07 and further there is additional sticker added to package for protection reasons, as showm below.90005 90002 90139 90005 90002 WHITENING, ANTI-AGING MOISTURIZING 90005 90002 90005 90002 90003 100% human Placenta Laennec (Original, Directly from Japan — from Maker and official distributor). 90004 90005 90002 90005 90002 90005 90002 90003 ALSO CHECK LAENNEC — 50 pcs — FOLLOW THE LINK 90004 90005 90002 90003 90159 90004 90005 90002 90003 LAENNEC — 50 pcs 90004 90005 90002 90005 90002 Effective for: 90005 90002 90005 90002 1.general fatigue 2.Stiffness of shoulders 3.Astma 4.Urticaria (hives) 5.Migraine 6. Prostatic hypertrophy 7.Menopause 8. Andropause (male enopause) 9. Dysmenorrhea 10.Ovarian Dysfunction 11.Frigidity 12.Oligogalactia 13. Gestational toxicosis 14.Chronic constipation 15. Gastroptosis 16.Gastric ulcer 17. Stomack cancer 18.Dyspepsia 19.Hypertension 20.Hypotension 21.Neuralgia 22.Neurosis 23. Hepatitis 24. Liver cirrhosis 25. Retinal pigmenttary dystrophy 26.Cataract 27.Iritis 29. Hearing loss 30.Tinnitus 31.Anemia 32.raynaud disease 33.lupus 34.Nocturnal Enurosis (bed-wetting) 35.Eczema 36.Melasma 37.Skin Allergy 38.Skin cancer 39.Keloid scar. 90005 90002 90005 90002 100% HUMAN PLACENTA EXTRACT 90005 90002 90005 90002 The fact that 100% Human Placenta Extract was proven to be beneficial to human body. Japanese government had no doubts in acknowledging it as an alternative medicine for anti-aging program. Even the American Food and Drug Agency did conform with the Japanese Government on this issue.Knowing the high medical standard of the Japanese government, 100% HPE has meticulously pass its standards. Undoubtful and sure, most of the modern beauty enthusiasts has been using 100% for ANTI-AGING, WHITENING and MOSTURIZING agent. Which is, BETTER than BOTOX. It also harmless and more compatible for humans to use rather than from four legged animals. And take note, 100% HPE is not only for anti-aging programs! It has also many benefits to offer for human. The following mentioned below are just some of the ailment that can be treated by 100% HPE.90005 90002 90005 90002 Certified in Japan, Korea, USA, this is currently the most reliable and effective injectable drug. 90005 90002 90005 90002 90003 Official Japanese Certificate. 90004 90005 90002 90193 90005 .90000 LAENNEC | μ£Όμνμ¬ μΌλ³Έ μλ¬Ό μ μ 90001 90002 Laennec is the ethical drug manufactured with JBP’s unique technologies. 90003 90004 Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver.Our product safety is ensured by the most rigid safety measures among existing scientific standards. 90005 90004 90007 Warning: 90008 90007 As the LAENNEC Injection is an ethical drug, JBP has never sold it on Internet. 90008 90005 90012 90013 90014 90015 90016 90015 Ingredients 90016 90015 Content 90016 90015 Remarks 90016 90023 90014 90015 Active ingredient 90016 90015 Water-soluble substance of a product of enzymatic human placenta 90016 90015 112 mg 90016 90015 Ingredient extracted from human placenta 90016 90023 90014 90035 Inactive ingredients 90016 90015 Pepsin 90016 90015 Trace 90016 90015 Gastric mucosal extract (pig) 90016 90023 90014 90015 Lactose 90016 90015 0.6 mg 90016 90015 — 90016 90023 90014 90015 pH adjuster 90016 90015 q.s. 90016 90015 — 90016 90023 90060 90061 90004 90007 Description 90064 90008 This product is a light yellow-brown or yellow-brown clear liquid with a distinctive odor. The pH level ranges from 5.5 to 6.5 and the osmotic pressure ratio (to physiological saline) is approximately one. 90005 90004 90007 Indications 90064 90008 Improvement of hepatic function in chronic hepatic disease.90005 90004 90007 Dosage and administration 90064 90008 The normal adult dose is a 2 ml subcutaneous or intramuscular injection once daily. According to symptoms, the dose can be increased to 2 or 3 times daily. 90005 90004 90007 Packaging 90064 90008 2 ml 50 ampoules 90005 90002 Cautions for use ** 90007 90008 90003 90004 90007 1. Careful Administration 90064 90008 LAENNEC should be administrated with care in patients predisposed to allergies. 90005 90004 90007 2. Important Basic Cautions 90064 90008 This product is manufactured from the extract of human placenta delivered full-term in Japan.In order to screen each donor, a complete medical history, interviewing such as a history of travel and serologic testing for viruses, bacteria and infection are performed, after nucleic-acid testing (NAT) to meet with requirements for HBV-DNA, HCV- RNA and HIV-1-RNA is carried out. In addition, it has been confirmed that high-pressure steam sterilization for 20 minutes at 121 Β° C during the manufacturing process is effective in inactivating various viruses such as HIV etc. Furthermore, although in the product test, the nucleic-acid test meets with requirements for HBV-DNA, HCV-RNA, HIV-1-RNA, HTLV-DNA, and parvovirus B19-DNA, patients should be made aware of the following points during administration: To date, the transmission of infection, such as variant Creutzfeldt-Jakob disease (vCJD), by administration of this product in Japan or other countries has not been reported.However, although safety measures are taken to prevent infection during the manufacturing process, it is theoretically impossible to fully eliminate the risks of infection transmission originating in a human placenta used as raw material. While safety measures during the manufacturing process to prevent infection, as well as confirmation of the necessity of treatment for the disease before administration are carried out, doctors should explain to patients and try to have them understand that when human placenta is used as the raw material of a product, the risk of infection can not be fully ruled out.90005 90004 90007 3. Drug Interactions 90064 90008 When this product is directly mixed with a strong base preparation of pH 8.5 or more, attenuation of pharmacological activity has been reported. 90064 No coadministration with this product resulting in the enhancement or attenuation of the pharmacological effect of this product or concomitant drugs, appearance of adverse reactions, or aggravation of disease has been reported. 90005 90004 Adverse reactions or patients who were suspected to have suffered adverse reactions to this product were reported in a total of 10 (3.7%) of the 273 patients selected for safety evaluation in the clinical study performed during implementation of reevaluation of the drug efficacy. The most frequently observed adverse reactions were injection site pain in 7 patients (2.6%), hypersensitivity (such as rash, fever, and itching) in 1 patient (0.4%), injection site indurations in 1 patient (0.4%), and gynaecomastia in 1 patient (0.4%). The causal relationship between gynaecomastia and this product is unknown. 90064 No abnormal changes in laboratory values ββwere observed.90104 1) 90064 90106 β’ Clinically significant adverse reactions 90064 ** Shock (incidence unknown): 90064 Since this product is a protein / amino acid preparation derived from human tissue, this product may cause a shock. If any signs of abnormality are observed, the drug should be discontinued immediately, appropriate measures should be taken and the condition should be monitored fully. 90064 β’ Other adverse reactions (in descending order of occurrence) 90005 90111 90013 90014 90015 Injection site pain 90016 90015 2.56% 90016 90023 90014 90015 Sensitivity (rash, fever, itching etc.) 90016 90015 0.37% 90016 90023 90014 90015 Injection site indurations 90016 90015 0.37% 90016 90023 90014 90015 Gynaecomastia 90016 90015 0.37% 90016 90023 90060 90061 90004 90007 4. Use in the Elderly 90064 90008 From clinical data and present use, no particular caution is needed in the administration of this product to the elderly.However, since elderly patients often have reduced physiological function, it should be administrated with care. 90005 90004 90007 5. Use during Pregnancy. Delivery or Lactation 90064 90008 In reproductive development toxicity experiments on animals, including teratogenicity, this product can be considered not to have such toxicity. 90104 2) 90106 90005 90004 90007 6. Pediatric use 90064 90008 The safety of this product in premature infants, newborns, infants, toddlers or children has not been established due to insufficient clinical data.90005 90004 90007 7. Overdosage 90064 90008 Overdosage of this product and the resulting efficacy or safety have not been established (Due to insufficient clinical data). 90005 90004 90007 8. Precautions for Use 90064 90008 Injection site: 90064 In order to avoid any effect on tissue or nerves, the product should be injected subcutaneously or intramuscularly taking the following precautions: 90064 a) For the injection site, to avoid nerve pathways, it should be administrated with care.90064 b) In the case of repeated injections, avoid injecting into the same site by alternating on the left and right side etc. 90064 c) If intense pain or regurgitation of blood is observed, the needle should be removed immediately, and injected into a different site. 90064 Opening the ampoule: 90064 When opening the ampoule, it is preferable to wipe the part to be cut with an ethanol sponge before opening it. 90005 90004 90005 90002 Pharmacokinetics 90003 90004 The bioactive ingredients of LAENNEC are extracted from human placenta, and the primary pharmacological effects of this product can not necessarily be attributed to a single substance or ingredient.Therefore, evaluation of the pharmacokinetics (absorption, distribution, metabolism, and excretion) of this product has not been established. 90005 90004 90005 90002 Clinical studies 90003 90004 90007 1. Double blind comparison to chronic hepatitis and hepatic cirrhosis 90104 1) 90064 90106 90008 In a double-blind crossover study of 124 patients in Japan on the effects of this product on chronic hepatitis and hepatic cirrhosis, administration of this product improved serum transaminase (GOT, GPT) levels significantly (see figures below).90005 90004 Efficacy to GOT 90064 90005 90004 Efficacy to GPT 90064 90005 90004 Summary of drug-efficacy 90064 [(A) Items having a tendence to decrease or increase significantly by Laennec] 90005 90004 Data on pharmacological reevaluation 90064 Summary of drug-efficacy 90064 [(B) Items having a tendence to decrease or increase significantly by Placebo] 90005 90004 90007 2. Action on HCV-RNA levels 90104 3) 90064 90106 90008 Twenty subjects of two-agent combination therapy only with Stronger Neo-Minophagen C and Acelart were performed in the past and negativation neither of C100-3 antibody nor HCV-RNA was admitted in them.In three-agent combination therapy with Laennec added, two negative cases of serum HCV-RNA levels were admitted. 90005 90004 90005 90002 Pharmacology 90003 90004 90007 1. Stimulatory effects of hepatic reproduction 90104 4), 5) 90064 90106 90008 After 70% of livers in healthy rats was resected, time comparisons of liver weight to the control groups resulted in significant stimulation of hepatic reproduction in the Laennec groups. 90005 90004 90007 2. Stimulatory effects of cellular DNA synthesis 90104 4) 90064 90106 90008 Compared to control groups, in vivo experimental system using primary culture rat hepatocytes, the DNA-synthesis accelerator activity was observed in 2 ΞΌL / ml-administrated groups.That accelerator activity was equivalent to 10 pM of rHGF. The liver tissue in vivo experimental system using rats with acute hepatitis by ANIT was stained and the result of evaluation of the rate of hepatocyte nucleus in DNA synthesis period showed significant accelerator of DNA synthesis compared to the control groups. 90005 90004 90007 3. Inhibitory effects of experimental liver injury 90104 4), 6) 90064 90106 90008 Compared to control groups, in vivo experimental system using rats with acute hepatitis by ANIT, the liver cytosolic enzymes in serum (GPT, ALP, LAP and g -GTP) and the bilirubin levels significantly degreased in the Laennec groups.90064 In addition, compared to control groups, in vivo experimental system using rats with acute hepatitis and chronic hepatitis by CCI4, the liver cytosolic enzymes in serum (GPT, GOT) significantly degreased and histopathologically improved liver disorder in the Laennec groups. 90005 90004 90007 4. Anti-fatty liver action 90104 7) 90064 90106 90008 A 5-day subcutaneous injection of 1.2 ml / kg of this product in rats suffering from acute hepatic disorder with CCI4 resulted in a significant decrease in hepatic weight to body weight as compared with the control groups.Furthermore, total hepatic lipids and total hepatic cholesterol decreased significantly in the 3.6 ml / kg dose groups, and hepatohistological findings to support such results were seen and the body weight was realized. 90064 After pretreatment of acute hepatic disorder with CCI4, there were no significant differences with regards to biochemical findings between the control groups and when 5-day repeated, subcutaneous administration of 1.2 ml / kg of this product was performed. However, in the 3.6-ml / kg dose groups, maintenance of lobular structure was better than the control groups with regards to hepatohistological findings.90005 90004 90007 5. Absorption accelerated activity on interstitial connective tissue 90104 8) 90064 90106 90008 This product exhibited inhibitory action of fibroplasias in rat liver due to 12-week repeated administration of CCI4, and it was confirmed histologically that once multiplied, interstitial connective tissues were absorbed. 90005 90004 90005 90002 Physicochemistry 90003 90004 This product is human-placental extract, and contains various biological active substances. However, the active ingredients of this agent can not be specified as a single substance or several sorts of substances.90005 90004 90005 90002 Precautions for handling * 90003 90004 This product corresponds to a specialized biological product. Therefore, when this product is administrated, the product name, manufacturing No., date of administration (or prescription), name and address of patients should be reported and stored for at least 20 years in accordance with the order issued by the Japanese Ministry of Health, Labour and Welfare. This product should be used with attention to the point that the indication of this product is «improvement of hepatic function in chronic liver disease».90005 90004 90005 90004 90007 References 90064 90008 1) Ueda H. et al .: Kanzo (Liver), vol.15, 162, 1974 90064 2) Taniguchi H. et al .: data on file in Japan Bio Products Co. Ltd., 1985-1991 90064 3) Takami T .: Kiso to Rinsho, vol.30, 3549, 1996. 90064 4) Liu K. et al .: Yakuri to Rinsho, vol.5, 2187, 1995 90064 5) Sakamoto K . et al .: Journal of Tokyo Medical University, vol.33, 271, 1975 90064 6) Nakayama S. et al .: Folia Pharmacologica Japonica, vol.94, 289, 1989 90064 7) Sakamoto K. et al.: Journal of Tokyo Medical University, vol.31, 829, 1973 90005 .